## Past and Current ISOPP Presidents

<table>
<thead>
<tr>
<th>Year</th>
<th>City, Country</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>1995-1998</td>
<td>Deutschland, Deutschland</td>
<td>Helen McKinnon</td>
</tr>
<tr>
<td>1998-2000</td>
<td>Deutschland, Deutschland</td>
<td>Klaus Meier</td>
</tr>
<tr>
<td>2000-2002</td>
<td>Deutschland, Deutschland</td>
<td>Larry Broadfield</td>
</tr>
<tr>
<td>2002-2004</td>
<td>Deutschland, Deutschland</td>
<td>Barry Goldspiel</td>
</tr>
<tr>
<td>2004-2006</td>
<td>Deutschland, Deutschland</td>
<td>Graham Sewell</td>
</tr>
<tr>
<td>2006-2010</td>
<td>Deutschland, Deutschland</td>
<td>Carole Chambers</td>
</tr>
<tr>
<td>2010-2012</td>
<td>Deutschland, Deutschland</td>
<td>Johan Vandenbroucke</td>
</tr>
<tr>
<td>2012-2014</td>
<td>Deutschland, Deutschland</td>
<td>John Wiernikowski</td>
</tr>
<tr>
<td>2014-2016</td>
<td>Deutschland, Deutschland</td>
<td>Rowena Schwartz</td>
</tr>
<tr>
<td>2016-2018</td>
<td>Deutschland, Deutschland</td>
<td>Harbans Dhillon</td>
</tr>
</tbody>
</table>

## ISOPP Symposia Locations

<table>
<thead>
<tr>
<th>Year</th>
<th>City, Country</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>1988</td>
<td>Rotorua, New Zealand</td>
<td>Helen McKinnon</td>
</tr>
<tr>
<td>1990</td>
<td>Exeter, United Kingdom</td>
<td>Graham Sewell</td>
</tr>
<tr>
<td>1993</td>
<td>Toronto, Canada</td>
<td>Larry Broadfield</td>
</tr>
<tr>
<td>1995</td>
<td>Hamburg, Germany</td>
<td>Klaus Meier</td>
</tr>
<tr>
<td>1997</td>
<td>Sydney, Australia</td>
<td>Terry Maunsell</td>
</tr>
<tr>
<td>1998</td>
<td>Washington, USA</td>
<td>Jim Koeller</td>
</tr>
<tr>
<td>2000</td>
<td>Prague, Czech Republic</td>
<td>Martin Benes</td>
</tr>
<tr>
<td>2002</td>
<td>Vancouver, Canada</td>
<td>Jeff Barnett, Kimberley Stefaniuk</td>
</tr>
<tr>
<td>2004</td>
<td>Torino, Italy</td>
<td>Franca Goffredo</td>
</tr>
<tr>
<td>2006</td>
<td>Kuala Lumpur, Malaysia</td>
<td>Saad Othman, Helen Leather</td>
</tr>
<tr>
<td>2008</td>
<td>Anaheim, USA</td>
<td>Helen Leather</td>
</tr>
<tr>
<td>2010</td>
<td>Prague, Czech Republic</td>
<td>Carole Chambers</td>
</tr>
<tr>
<td>2012</td>
<td>Melbourne, Australia</td>
<td>Terry Maunsell</td>
</tr>
<tr>
<td>2014</td>
<td>Montreal, Canada</td>
<td>Carlo DeAngelis</td>
</tr>
<tr>
<td>2016</td>
<td>Santiago, Chile</td>
<td>Alejandra Barahona</td>
</tr>
<tr>
<td>2017</td>
<td>Budapest, Hungary</td>
<td>Attila Szucs</td>
</tr>
</tbody>
</table>
Welcome from the ISOPP President

Bienvenidos a ISOPP dos mil dieciseis. On behalf of the International Society of Oncology Pharmacy Practitioners (ISOPP) leadership, it is my great pleasure to welcome you to ISOPP XV, our first ISOPP meeting in South America.

It is here, surrounded by the snow-capped Andes and the Chilean Coastal Range, that we celebrate ISOPP’s 20th anniversary with the help of our gracious hosts, members of Capitulo de Quimicos Farmaceuticos de Oncologia (CQFO), also known as the Chapter of Chilean Oncology Pharmacists.

There are many people to thank and acknowledge for the success of this Symposium and celebration of ISOPP. Thank you to our Symposium Chair, Alejandra Barahona and Program Co-Chairs, Alexandre Chan and Sulamita Miranda Nam, the Planning Committee and the Scientific Program Committee for their leadership in organizing this Symposium. Thank you to the program faculty for joining us. Also, I would like to thank our sponsors who provide invaluable support for the Symposium and ISOPP. And thank you to all the volunteers who give of their time and make us feel so welcome.

I encourage you to take advantage of the wide range of activities of ISOPP XV, including the scientific sessions, posters, exhibits and social functions that provide an opportunity to network and meet oncology pharmacist from across the globe. Make sure to join us in the celebration of ISOPP’s 20th Anniversary during the Opening Ceremonies and the Social Event on Tuesday, and of course, to the Annual General Meeting on Tuesday where we will discuss the strategic plan for ISOPP, and start to design the future for our organization. Also, you are all invited to join the present and past ISOPP leadership at the ‘Explore ISOPP Opportunities’ Reception to find out more about what ISOPP can do for you and how you can be involved in ISOPP. Look for us in the San Cristobal Foyer on Tuesday.

Again, thank you to our hosts in beautiful Santiago. I hope you all find some time to explore Chile’s fascinating capital.

I look forward to seeing you throughout the Symposium.

Rowena (Moe) Schwartz
President, ISOPP
McKesson Specialty Health,
The Woodlands, TX, USA
Welcome from the Symposium Chair and President of the Chapter of Chilean Oncology Pharmacists (Capítulo de Químicos Farmacéuticos de Oncología)

On behalf of Químicos Farmacéuticos de Oncología, the Chapter of Chilean Oncology Pharmacists, it is my pleasure to welcome you to the XV International Symposium on Oncology Pharmacy Practice (ISOPP 2016).

Welcome to beautiful Santiago, the capital city of Chile. While in Santiago please take some time to immerse yourselves in our history and culture. Enjoy the food, architecture, landscape and many attractions available at your doorstep.

The theme of ISOPP XV is Oncology Pharmacy Practice – A Global Perspective. Oncology practice is changing day by day, and the role of oncology pharmacists continues to grow and evolve. The Symposium will provide oncology pharmacy professionals with essential updates to enhance their work and examples of best practice from around the world.

A special thank you to my Scientific Program Committee Co-Chairs, Sulamita Miranda Nam and Alexandre Chan and all the members of the Program and Planning Committees who have shown much dedication over the past months. I also want to thank the presenters for sharing their knowledge and challenging us to think in new ways. In addition, I extend huge appreciation to our sponsors for their generous support.

Please enjoy the Symposium, the exhibition and posters, the wonderful city of Santiago, and the Chilean hospitality.

Alejandra Barahona
Symposium Chair and President of Capítulo de Químicos Farmacéuticos de Oncología
Hospital del Salvador, Santiago, Chile
Symposium: Biologics & Biosimilars: pharmacovigilance, interchangeability and extrapolation of indications

Hotel Sheraton Santiago
Room Pedro de Valdivia AB
April 18th 2016
13:00 - 14:30

Dr. Renato Murillo Masís
PhD in Chemistry
Costa Rica University
Welcome from the Scientific Program Committee Co-Chairs

On behalf of the Scientific Program Committee, it is our honor to welcome you to the XV International Symposium on Oncology Pharmacy Practice (ISOPP 2016).

The Committee has worked diligently to bring you a highly education-enhancing program which will address cutting edge topics during four plenary, three panel and nine concurrent sessions addressing clinical, research and fundamental topics in oncology practice. New ideas will be shared in posters and platform presentations and up-to-date information presented in sponsored satellite symposia and sponsor and exhibitor displays.

It has been a pleasure to work in collaboration with the Chapter of Chilean Oncology Pharmacists to bring you this outstanding Oncology Pharmacy Symposium with the theme Oncology Pharmacy Practice – A Global Perspective.

ISOPP 2016 is a great opportunity for us to come together to share successes, discuss challenges and learn from and be inspired by one another. The connections you will make here will help you advance your profession from so many different angles.

Thank you to our speakers, sponsors and volunteers. Have fun in Santiago and enjoy the Symposium!

Sulamita Miranda Nam
Assistant Professor and Specialist Pharmacist
Andrés Bello University, Santiago, Chile

Alexandre Chan
Associate Professor and Specialist Pharmacist
National University of Singapore, Singapore
National Cancer Centre Singapore, Singapore
Hospital Pharmacists Taking the Lead: How Can Guideline Based Standing Orders/Pathways Enhance Effective CINV Patient Care?

Tuesday, 19 April 2016
13:00 – 14:00

Sheraton Santiago Hotel
Room: Pedro de Valdivia AB
Santiago, Chile

Chair: David Warr (Canada)

AGENDA

13:00 – 13:05 Welcome and Introductions  David Warr
13:25 – 13:45 The Pharmacist’s Role Establishing CINV Protocols/Formularies  Annemerli Livinalli
13:45 – 14:00 Q&A and Closing Remarks  Faculty
Program at a Glance

This program is interactive, click on session titles to jump to the detailed program and find out more about your selected session.

Simultaneous Interpretation from English to Spanish is provided during plenary and panel sessions in Pedro de Valdivia AB and concurrent sessions in Pedro de Valdivia C and El Quixote. Simultaneous Interpretation from Spanish to English is provided for the Roche Satellite Symposium. Sessions with Simultaneous Interpretation are indicated with this symbol.

Sunday, April 17

09:00-12:30
Pre-Symposium Workshop (Pedro de Valdivia C)
This session will be presented in Spanish with some English.

15:00 – 16:15
Opening Ceremonies (Pedro de Valdivia AB)
Rowena Schwartz, ISOPP President, McKesson Specialty Health, The Woodlands, TX, USA
Alejandra Barahona, Symposium Chair, Hospital del Salvador, Santiago, Chile
Sulamita Miranda Nam, Scientific Program Committee Co-Chair, Andrés Bello University, Santiago, Chile
Alexandre Chan, Scientific Program Committee Co-Chair, National University of Singapore, Singapore

16:15 – 17:15
Opening Plenary (Pedro de Valdivia AB)
Access to Cancer Medicines: Global Disparities Deserve Global Attention
Julie Torode, Union for International Cancer Control (UICC), Geneva, Switzerland

Monday, April 18

09:00 – 09:45
Plenary (Pedro de Valdivia AB)
Novel Immunotherapy for Melanoma: Mechanisms, Outcomes, and Future Strategies
R. Donald Harvey, Winship Cancer Institute of Emory University, Atlanta, GA, USA
09:45 – 10:15  
**Refreshment Break** *(Exhibit and Poster Hall, San Cristobal)*

10:15 – 11:00  
**Plenary** *(Pedro de Valdivia AB)*
Clinical Impact and Recent Outcomes of Immunotherapy in Solid Tumours: Is it the Pathway for Cancer Cure?  
Christian Caglevic, Fundación Arturo López Pérez, Santiago, Chile

11:00 – 12:00  
**Concurrent Sessions 1**

**Clinical 1A: Solid Tumor Updates** *(Pedro de Valdivia C)*
- **Solid Tumor Update: Lung Cancer**  
  Evelyn Handel, National Comprehensive Cancer Network, Ambler, PA, USA
- **Solid Tumor Update: Breast Cancer**  
  Kellie Jones Weddle, Purdue University, Indianapolis, IN, USA

**Research 1B: Research with Complementary Alternative Medications in Oncology** *(El Quixote)*
Judyth Smith, The University of Texas Health Science Center at Houston Medical School, Houston, TX, USA

12:00 – 13:00  
**Concurrent Sessions 2**

**Clinical 2A: Antiemetic Updates** *(Pedro de Valdivia C)*
- **Antiemetic Update: Olanzapine**  
  Alexandre Chan, National University of Singapore, Singapore
- **Antiemetic Update: New NK-1 Antagonists**  
  Ivonne Flores, Fundación Arturo López Pérez, Santiago, Chile

**Fundamental 2B: Pharmacovigilance Plan for Biologics and Biosimilar Antibodies: Is it Really Useful?** *(El Quixote)*
Alain Astier, Henri Mondor University Hospitals, Créteil, France

**Research 2C: Epigenetic Bases of Gastric Cancer: From Pathogenesis to the Potential Identification of New Targets for Prevention and Treatment** *(O’Higgins)*
Alejandro Corvalán, Pontificia Universidad Catolica de Chile, Santiago, Chile
13:00 – 14:30
Satellite Symposium – Roche Chile (Pedro de Valdivia AB)
Biological and Biosimilars: Pharmacovigilance, Interchangeability and Extrapolation of Indications / Biológicos y Biosimilars: farmacovigilancia, intercambiabilidad y extrapolación de indicaciones
Renato Murillo, Profesor Caedrático, Universidad de Costa Rica, Costa Rica
This session will be presented in Spanish with Simultaneous Interpretation into English.

13:00 – 14:30
Lunch amongst the Exhibits and Posters (Exhibit and Poster Hall, San Cristobal)

14:30 – 16:00
Concurrent Sessions 3

Clinical 3A: Pediatrics/Adolescents/Young Adults Update (Pedro de Valdivia C)
- Description of Tools Pharmaceutical Care in Acute Lymphoblastic Leukemia (Pharmacogenomics) Hospital Pediatric Experience Chilean Program Associated with Antineoplastic Drugs (PINDA)
  Jorge Morales Vallespín, Hospital Dr. Luis Calvo Mackenna, Santiago, Chile
- Update on Paediatric Bone Tumours
  John Wiernikowski, McMaster Children’s Hospital, Hamilton, ON, Canada

Fundamental 3B: USP 800 Implementation and Practical Considerations (El Quixote)
- USP 800 Implementation: Considerations Across Practice Settings
  Rowena Schwartz, McKesson Specialty Health, Woodlands, TX, USA
- USP 800 Implementation: A Case Study at the National Cancer Center Hospital East, Japan
  Shinya Suzuki, National Cancer Center Hospital East, Kashiwa, Japan

Fundamental 3C: Education, Competency and Mentorship (O’Higgins)
  Judith Smith, The University of Texas Health Science Center at Houston Medical School, Houston, TX, USA
  Barry Goldspiel, National Institutes of Health Clinical Center, Bethesda, MD, USA

16:00 – 16:30
Refreshment Break (Exhibit and Poster Hall, San Cristobal)
16:30 – 18:00
Concurrent Sessions 4

Fundamental 4A: Oral Medication Adherence and Management in Oncology (Pedro de Valdivia C)

- Oral Medication Adherence and Management in Oncology
  Steve Stricker, Takeda Oncology, Florence, KY, USA
- Strategies to Improve Oral Medication Adherence in Oncology
  Harbans Dhillon, University Malaya Medical Centre, Kuala Lumpur, Malaysia

Research 4B: Investigational Agents Update (El Quixote)

- Rowena Schwartz, McKesson Specialty Health, The Woodlands, TX, USA
- R. Donald Harvey, Winship Cancer Institute of Emory University, Atlanta, GA, USA

Clinical 4C: Oncology Patients and Special Circumstances (O’Higgins)

- Incidence of Drug-Induced Liver Injury in Patients Hospitalized at The Instituto Nacional de Enfermedades Neoplasicas Lima
  Martha Estacio, Instituto Nacional de Enfermedades Neoplasicas Eduardo Caceres Graziani, Lima, Peru
- Cancer in Pregnancy
  Peter Gilbar, Toowoomba Hospital, Toowoomba, Australia

Tuesday, April 19

09:00 – 10:00
Plenary (Pedro de Valdivia AB)

Dermatologic Toxicities: The Superficial Side of Targeted Therapies

Milan J. Anadkat, Washington University School of Medicine, St. Louis, MO, USA

10:00 – 10:30
Refreshment Break (Exhibit and Poster Hall, San Cristobal)
Sponsored by Grifols

GRIFOLS

10:30 – 11:30
Concurrent Sessions 5

Clinical 5A: Hematological Cancer Updates (Pedro de Valdivia C)

- Hematological Cancer Update: Chronic Lymphocytic Leukemia (CLL)
  Tara Leslie, Tom Baker Cancer Centre and University of Alberta, Calgary, AB, Canada
- Hematological Cancer Update: Lymphomas
  Alexandre Chan, National University of Singapore, Singapore
Fundamental 5B: Lean Thinking with the Toyota Production System (El Quixote)  
Shaun O’Connor, Box Hill Hospital (Eastern Health), Box Hill, VIC, Australia

Clinical 5C: End of Life Care Discussion Session (O’Higgins)  
Peter Gilbar, Toowoomba Hospital, Toowoomba, Australia

11:30 – 13:00  
ISOPP Annual General Meeting (Pedro de Valdivia C)  

13:00 – 14:00  
Satellite Symposium – Merck (Pedro de Valdivia AB)  
Hospital Pharmacists Taking the Lead - How Can Guideline Based Standing Orders / Pathways Enhance Effective CINV Patient Care  
David Warr, Princess Margaret Hospital, Toronto, ON, Canada  
Annemeri Livinalli, Sociedade Brasileira de Farmacêuticos em Oncologia, São Paulo, Brazil

13:00 – 14:30  
Lunch amongst the Exhibits and Posters (Exhibit and Poster Hall, San Cristobal)

14:30 – 15:15  
Panel (Pedro de Valdivia C)  
Developing to Established….How to Define Oncology Pharmacy as a Specialty  
Panellists: Harbans Dhillon, University Malaya Medical Centre, Kuala Lumpur, Malaysia  
Tara Leslie, Tom Baker Cancer Centre and University of Alberta, Calgary, AB, Canada  
Annemeri Livinalli, Sociedade Brasileira de Farmacêuticos em Oncologia, São Paulo, Brazil  
Klaus Meier, Heidekreis-Klinikum GmbH, Soltau, Germany  
Shaun O’Connor, Box Hill Hospital (Eastern Health), Box Hill, VIC, Australia  
Rowena Schwartz, McKesson Specialty Health, The Woodlands, TX, USA  
Moderator: Kellie Jones Weddle, Purdue University, Indianapolis, IN, USA

15:15 – 16:15  
Concurrent Sessions 6  
Clinical 6A: Supportive Care Updates (Pedro de Valdivia C)  
- Supportive Care Update: Alopecia  
  Milan J. Anadkat, Washington University School of Medicine, St. Louis, MO, USA  
- Supportive Care Update: Antibiotic Prophylaxis for Infections  
  Claudio Gonzalez, Unidad Oncologia, Hospital pediátrico Exequiel González Cortés, Santiago, Chile
Clinical 6B: Bone Marrow Transplant Update (El Quixote)

• Role of the Clinical Pharmacist in a Stem Cell Transplantation Ward
  Tiene Bauters, Ghent University Hospital, Ghent, Belgium
• Bone Marrow Transplant Update
  Pablo Ramirez, Catholic University, Santiago, Chile

Research 6C: How to Write Your First Grant (O’ Higgins)

Judith Smith, The University of Texas Health Science Center at Houston Medical School, Houston, TX, USA
R. Donald Harvey, Winship Cancer Institute of Emory University, Atlanta, GA, USA

16:15 – 18:00
Refreshment Break, Poster and Exhibit Viewing Session (Exhibit and Poster Hall, San Cristobal)

17:45 – 18:30
“Explore ISOPP Opportunities” Reception (San Cristobal Foyer)

19:30 – 23:00
ISOPP 20th Anniversary Dinner Chilean Style (Pedro de Valdivia AB)

Wednesday, April 20

09:00 – 10:00
Platform Presentations (Pedro de Valdivia AB)
Facilitator: Judith Smith, ISOPP Research Chair, The University of Texas Health Science Center at Houston Medical School, Houston, TX, USA

10:00 – 10:30
Refreshment Break (Exhibit and Poster Hall, San Cristobal)
10:30 – 11:30
Panel (Pedro de Valdivia AB)
Global Impact of Cancer Care
Moderator: John Wiernikowski, McMaster Children’s Hospital, Hamilton, ON, Canada

11:30 – 13:00
Concurrent Sessions 7

Clinical 7A: Optimizing Care in the Older Adult with Cancer (Pedro de Valdivia C)
Rowena Schwartz, McKesson Specialty Health, The Woodlands, TX, USA
Annemeri Livinalli, Sociedade Brasileira de Farmacêuticos em Oncologia, São Paulo, Brazil

Research 7B: How Pharmacists Can Integrate Research into Daily Oncology Practice (El Quixote)
Judith Smith, The University of Texas Health Science Center at Houston Medical School, Houston, TX, USA
Tiene Bauters, Ghent University Hospital, Ghent, Belgium
Rosalyn Sims, Children’s Hospital of Michigan, Troy, MI, USA

13:00 – 14:30
Satellite Symposium – BD Medical (Pedro de Valdivia AB)
Mitigating Risk During Hazardous Drug Handling: Improving the Practice of Safe Handling of Hazardous Drugs
Johan Vandenbroucke, Ghent University Hospital, Ghent, Belgium

13:00 – 14:30
Lunch amongst the Exhibits and Posters (Exhibit and Poster Hall, San Cristobal)

14:30 – 15:30
Concurrent Sessions 8

Clinical 8A: Application of Pharmacogenomics in Daily Clinical Practice (Pedro de Valdivia C)
Mario Chiong Lay, University of Chile and Advanced Center for Chronic Diseases (ACCDiS), Santiago, Chile

Fundamental 8B: Communicating Medical and Oncology Information to Health Care Professionals and Patients (El Quixote)
- Twitter and Virtual Journal Club: Stay Up to Date with Distance Learning
  Felice Musicco, Istituti Fisioterapici Ospitalieri Regina Elena San Gallicano, Rome, Italy
- Social Media in Oncology, Risk and Benefit
  Gustavo Espinoza, Central de preparaciones oncológicas REDSANA, Santiago, Chile

Research 8C: Interacting with Professional Journals: Reviewing and Publishing (O’Higgins)
Alexandre Chan, National University of Singapore, Singapore
Barry Goldspiel, National Institutes of Health Clinical Center, Bethesda, MD, USA
15:30 – 15:45
Refreshment Break (Pedro de Valdivia C / El Quixote / O’Higgins)

15:45 – 16:45
Concurrent Sessions 9

Clinical 9A: Gastrointestinal Tumors Update (Pedro de Valdivia C)
Jorge Gallardo, Clínica Alemana de Santiago, Instituto de Terapias Oncológicas Providencia, Santiago, Chile

Fundamental 9B: Dose Banding: Safety and Savings in One (El Quixote)
Carole R. Chambers, Tom Baker Cancer Clinic Pharmacy, Calgary, AB, Canada
Johan Vandenbroucke, Ghent University Hospital, Ghent, Belgium

Fundamental 9C: Tools and Methods for Pharmaceutical Care Plans and Documentation (O’Higgins)
- Tools and Methods for Pharmaceutical Care Plans and Documentation
  Klaus Meier, Heidekreis-Klinikum GmbH, Soltau, Germany
- Development and Implementation: The Tools required by Clinical Pharmacists to Conduct Safe Chemotherapy Checks
  Shinya Suzuki, National Cancer Center Hospital East, Kashiwa, Japan

16:45 – 18:00
Closing Panel (Pedro de Valdivia AB)
Cultural Diversity and Awareness in Oncology
Panellists: Sara Aguayo, Hospital Base San José Osorno, Osorno, Chile
Tiene Bauters, Ghent University Hospital, Ghent, Belgium
Harbans Dhillon, University Malaya Medical Centre, Kuala Lumpur, Malaysia
Peter Gilbar, Toowoomba Hospital, Toowoomba, Australia
Kellie Jones Weddle, Purdue University, Indianapolis, IN, USA
Shinya Suzuki, National Cancer Center Hospital East, Kashiwa, Japan
John Wiernikowski, McMaster Children’s Hospital, Hamilton, ON, Canada
Moderator: Rosalyn Sims, Children’s Hospital of Michigan, Troy, MI, USA

18:00 – 18:30
Awards and Closing Remarks (Pedro de Valdivia AB)
Judith Smith, The University of Texas Health Science Center at Houston Medical School, Houston, TX, USA
Barry Goldspiel, National Institutes of Health Clinical Center, Bethesda, MD, USA
Alejandra Barahona, Symposium Chair, Hospital del Salvador, Santiago, Chile
Rowena Schwartz, ISOPP Past President, McKesson Specialty Health, The Woodlands, TX, USA
Harbans Dhillon, ISOPP President, University Malaya Medical Centre, Kuala Lumpur, Malaysia

18:30 – 21:00
Capítulo de Químicos Farmacéuticos de Oncología Annual General Meeting
(Pedro de Valdivia C)
She fights fire with fire.

Again and again, with incredible precision, she prepares the chemotherapy dose. She knows the risk, but does it anyway. Because she knows the patients didn’t ask for this fight. And they need her to get it right.

Give her what she needs to help keep her safe.

BD PhaSeal System
Texium Compatible SmartSite® VialShield Device
Texium Bonded Syringe
Texium Administration Set with Integrated Drug Transfer Port

Contact your BD sales consultant today to learn more about the BD PhaSeal™ System and Texium® product line.
Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. Experience in Oncology drugs reconstituted in our innovative IV containers brings broader benefits to our customers and their patients.

Approved by the world’s leading regulatory authorities, our high quality, cost-effective cancer treatments meet world-class standards and are confidently used by healthcare professionals around the globe, from the USA through to Asia-Pacific.

We are dedicated to achieving excellence in everything we do, from meeting our customers’ needs through research and development, to supporting professional practice by sharing expertise and knowledge.

To find out more, visit us at www.fresenius-kabi.com
Venue Floor Plan

Sheraton Santiago Hotel
Ave Santa Maria 1742,
Santiago, Chile
sheraton.com/santiago
Telephone: +56-2-2233-5000

LEGEND
- Pre-Symposium Workshop, AGM, Concurrent Sessions
- Plenary, Satellite Symposia, Concurrent Sessions
- Exhibit and Poster Hall
- Concurrent Sessions

LOBBY LEVEL
- Entrance from Hotel Lobby

SAN CRISTÓBAL
- PRAT B
- COCHRANE
- O’HIGGINS

Z LEVEL (LOWER LEVEL)
- PEDRO DE VALDIVIA C
- PEDRO DE VALDIVIA A B

ELEVATORS
and BUSINESS CENTRE
Exhibits and Posters

Opening Hours

The following events will take place in the Exhibit and Poster Hall, located in San Cristobal, Lobby Level.

**Sunday, April 17, 17:15 – 18:30**
17:15 – 18:30  Welcome Reception   
* sponsored by Roche Chile*

**Monday, April 18, 09:30 – 16:30**
09:45 – 10:15  Refreshment Break  
13:00 – 14:30 Lunch  
16:00 – 16:30 Refreshment Break

**Tuesday, April 19, 09:30 – 18:00**
10:00 – 10:30  Refreshment Break   
* sponsored by Grifols*
13:00 – 14:30 Lunch  
16:15 – 18:00 Refreshment Break, Poster and Exhibit Viewing Session

**Wednesday, April 20, 09:30 – 14:30**
10:00 – 10:30 Refreshment Break
13:00 – 14:30 Lunch

Exhibitor Listing (alphabetical by company name)

<table>
<thead>
<tr>
<th>Company</th>
<th>Booth #</th>
</tr>
</thead>
<tbody>
<tr>
<td>BD MEDICAL</td>
<td>1</td>
</tr>
<tr>
<td>BRISTOL-MYERS SQUIBB</td>
<td>6</td>
</tr>
<tr>
<td>CESFAR/ REDSANAV CRUZVERDE</td>
<td>12</td>
</tr>
<tr>
<td>CHEMOGLO</td>
<td>4</td>
</tr>
<tr>
<td>EQUASHIELD LLC</td>
<td>14</td>
</tr>
<tr>
<td>FRESENIUS KABI</td>
<td>15</td>
</tr>
<tr>
<td>GALENICUM HEALTH CHILE SPA</td>
<td>13</td>
</tr>
<tr>
<td>GRIFOLS INTERNATIONAL</td>
<td>5</td>
</tr>
<tr>
<td>ICU MEDICAL</td>
<td>3</td>
</tr>
<tr>
<td>OMNICELL</td>
<td>2</td>
</tr>
<tr>
<td>ROCHE CHILE</td>
<td>9-10</td>
</tr>
<tr>
<td>SANDOZ, A NOVARTIS COMPANY</td>
<td>7-8</td>
</tr>
<tr>
<td>TEVA ONCOLOGY COMPANY</td>
<td>11</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Company</th>
<th>Table</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISOPP</td>
<td>T1</td>
</tr>
<tr>
<td>ONCOLOGY EDUCATION</td>
<td>T2</td>
</tr>
</tbody>
</table>
Exhibitor Listing (numerical by booth number)

Company ............................................ Booth #
BD MEDICAL ........................................ 1
OMNICELL ........................................ 2
ICU MEDICAL ....................................... 3
CHEMOGLO .......................................... 4
GRIFOLS INTERNATIONAL ..................... 5
BRISTOL-MYERS SQUIBB .......................... 6
SANDOZ, A NOVARTIS COMPANY .............. 7-8
ROCHE CHILE ....................................... 9-10
TEVA ONCOLOGY .................................... 11
CESFAR/ REDSANA/ CRUZVERDE .............. 12
GALENICUM HEALTH CHILE SPA .......... 13
EQUASHIELD LLC ................................... 14
FRESENIUS KABI .................................... 15

Exhibit and Poster Hall Floor Plan
EVERY DETAIL MATTERS. Medicine has the power to change life. We work relentlessly for a healthier future and are constantly improving our production and quality management.
Poster Listing

Please refer to the Journal of Oncology Pharmacy Practice 2016 Supplement to review poster abstracts. The JOPP supplement is provided as a PDF file on the USB key you received at registration and is also available online at opp.sagepub.com.

2015 Research Awardee

1 - Development of a Knowledge Competency Framework for Pharmacists Involved in Pharmaceutical Care for Hematopoietic Stem Cell Transplantation Patients
Tiene Bauters, Pediatric Hemato-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium

Clinical Sciences

6 - Assessment of Barriers to Good Medication Taking Behaviour in Metastatic Prostate Cancer Patients Receiving Oral Anti-Androgen Therapy
Soha Ahrari, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

7 - Impact of Clinical Pharmacists Counselling on Medication Adherence and Quality of Life among Cancer patients from a South Indian Hospital
Joy M. Anisty, Nitte University, Mangalor, KA, India

8 - Comparison Before/After the Creation of a Recall in the Prescription Software on the Association of Trace Elements and Vitamins in Parenteral Nutrition
Alain Astier, Hôpital Henri Mondor, Creteil, France

9 - An Audit of the Treatment and Management of Febrile Neutropenia
Kimberley-Ann Kerr, Lyell McEwin Hospital, Adelaide, SA, Australia

10 - A Drug Utilisation Review of Denosumab in Adult Patients with Cancer
Siew Woon Lim, National University Hospital, Singapore

11 - Health IT Impact in Oncology Clinical Management
Sandra A. Palacios García, The American British Cowdray Medical Center, Mexico City, Mexico

12 - Impact of Pharmacist-Led Telephone Intervention for Hypertension Due to Lenvatinib Oral Chemotherapy for Thyroid Cancer Patients
Shinya Suzuki, Division of Pharmacy, National Cancer Center Hospital East, Kashiwa, Japan

13 - Evaluating the Patient-Perceived Impact of Clinical Pharmacy Services and Proactive Follow-Up care in an Ambulatory Chemotherapy Unit
Malgorzata Tyszka, Princess Margaret Cancer Centre, Toronto, ON, Canada

14 - Assessment of Pharmacists Intervention at the Oncology Department in Kenyatta National Hospital
David Wata, Kenyatta National Hospital, Nairobi, Kenya

15 - A Retrospective Review on Trastuzumab-Induced Cardiotoxicity in Breast Cancer Patients In A Tertiary Hospital
Yuet Peng Wong, National University Hospital Pte Ltd, Singapore

Process Improvement / Pharmacoeconomics

16 - A Comparative Study To Evaluate Treatment Patterns and Resulting Utility In Patients of Head & Neck Cancers Under Private Payment Scheme and Government Reimbursement Scheme
Himanshu J. Patel, JSS College of Pharmacy, Mysore, JSS University, Mysore, KA, India

17 - Pharmacovigilance of Anti-Cancer Agents in a Developing Country: a Report through a Spontaneous Reporting and Intensive Monitoring System
Himanshu J. Patel, JSS College of Pharmacy, Mysore, JSS University, Mysore, KA, India

24 - Determining Contamination Levels Produced by the Handling of Antineoplastic Drugs in Limited-Resource Oncology Healthcare Settings, A Pilot Study
Claudio Müller Ramirez, Toxicología Facultad de Farmacia Universidad de Concepción, Concepción, Chile
Trainee Research

18 - Utilization of Capecitabine plus Oxaliplatin (CAPOX) and 5-Flourouracil/Folinic Acid plus Oxaliplatin (FFOX) in the Adjuvant Treatment of Stage II and Stage III Colon Cancer
Shirin Abadi, BC Cancer Agency, Vancouver, BC, Canada

19 - Assessment of Drug Interaction Voriconazole (VCZ) – Cyclosporine (CsA) in Bone Marrow Transplant Patients (BMT) (2013-2014)
Romina Valenzuela, Unit of Research, Department of Pediatrics and Surgery East, Faculty of Medicine, Universidad de Chile, Santiago, Chile
Jorge E. Morales, Hospital Dr. Luis Calvo Mackenna, Santiago, Chile

Encore Presentations

22 - The Project Oncology Competence Pharmacy: Improvement of Quality in German Oncology Pharmacies
Eva M. Schöning, Medac GmbH, Wedel, Germany

23 - Adherence To Abiraterone Among The First Sixty-six Recipients Following Its Release In Saskatchewan, Canada
Amy D. Smith, Saskatchewan Cancer Agency, Saskatoon, SK, Canada

Translational Science

20 - Pharmacokinetic Based Dosing of 5FU in Patients Treated with 5FU Infusional-based Regimens: Initial PK Observational Study
Michael Moloney, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

21 - Antioxidant Increases the Suppression of Oxaliplatin on the BRAF-mutant HT29 Tumorigenesis and Metastasis
Bo Yu, Fudan University Shanghai Cancer Center, Shanghai, China
International Society of Oncology Pharmacy Practitioners (ISOPP)

ISOPP Annual General Meeting
The ISOPP Annual General Meeting (AGM) will be held on Tuesday, April 19 from 11:30-13:00 in the Pedro de Valdivia C room on Z Level (Lower Level). All are welcome to attend and ISOPP members are encouraged to attend. Come ready to shape ISOPP’s future for the next twenty years.

About ISOPP
ISOPP connects oncology pharmacy experts from around the world. Through the society’s Symposia, journal (JOPP), newsletters and website, members can access leading edge oncology knowledge, best practices and essential professional networks. ISOPP also provides financial assistance through awards, grants, and reduced registration fees for members to the symposium and regional meetings, just one of the many benefits of membership.

The attendance by oncology pharmacists from more than 30 countries in our Symposia are a testament to our international impact. Through innovation, involvement and a shared passion for helping cancer patients, ISOPP members are able to make exceptional contributions to improved care.

Become a Member
ISOPP members’ number one priority is helping cancer patients with the best possible drug therapies. If you are an oncology practitioner providing clinical pharmacy and/or cytotoxic preparation services for cancer patients, ISOPP can help you achieve more in your profession.

Join us today and make connections with professionals who are part of healthcare teams involved in cancer prevention, treatment, supportive care, and symptom management. You’ll be joining a community that is at the forefront of efforts to prevent and manage toxicities associated with cancer treatment. You’ll also meet like-minded professionals involved in clinical and laboratory-based research, education, and management.

ISOPP exists to develop, improve and support the practice of oncology pharmacy for the benefit of individuals affected by cancer around the world. Membership comes with a great range of benefits. These include:

- Subscription to the bi-monthly Journal of Oncology Pharmacy Practice (JOPP) online and in hard copy
- Subscription to ISOPP’s quarterly ISOPP newsletter and its Community newsletter
- Eligibility for ISOPP travel and research grants as well as a variety of awards
- Reduced registration fees for high-quality international symposia to keep you up to date with developments in the field
- Networking opportunities with oncology practitioners from around the world through the online Discussion Forum and Member Listing
- Access to ISOPP’s Standards of Practice
- Joint membership of selected National Oncology Organizations
- Opportunities to participate in ISOPP Committees
- Eligibility to nominate for election to the ISOPP Secretariat
- Voting rights to determine the future of ISOPP
Travel Grant Winners

The following ISOPP members received Travel Grants to attend ISOPP 2016.

David Wata, Kenyatta National Hospital, Nairobi, Kenya
Himanshu Pate, JSS College of Pharmacy, Mysore, India
László Székely, Gideon Richter Plc, Budapest, Hungary

Society Management Office

International Society of Oncology Pharmacy Practitioners (ISOPP)
c/o Sea to Sky Meeting Management Inc.
Suite 206, 201 Bewicke Avenue
North Vancouver, BC, Canada   V7M 3M7
E: membership@isopp.org
T: +1-778-338-4142
F: +1-604-984-6434
www.isopp.org
Chapter of Chilean Oncology Pharmacists
Capítulo de Químicos Farmacéuticos de Oncología (CQFO)

CQFO Annual General Meeting
The Capítulo de Químicos Farmacéuticos de Oncología (CQFO) Annual General Meeting (AGM) will be held on Wednesday, April 20 from 18:30-21:00 in the Pedro de Valdivia C room on the Z Level (Lower Level). All are welcome to attend and CQFO members are encouraged to attend.

At the AGM we will analyze the last period of work of our group, provide information about all the activities planned for the upcoming year, and also hold the elections for the new Executive Committee.

About CQFO
Capítulo de Químicos Farmacéuticos de Oncología (CQFO), also known as the Chapter of Chilean Oncology Pharmacists was founded in September 2000 and is part of the Sociedad Chilena de Cancerología.

CQFO’s main focus is to: review and agree on safety standards in the preparation of chemotherapy, promote the implementation of government regulations and standards in this area, strengthen the role of clinical pharmacy in the care of cancer patients, disseminate scientific information, and encourage continuing education of pharmacists.

CQFO has organized six Conferences of Oncology Pharmacy with the participation of pharmacists from the whole country, in order to promote our role in the development of oncology:

- First Conference of Oncology Pharmacy, Olmue 2005
- Second Conference of Oncology Pharmacy, Jahuel 2007
- Third Conference of Oncology Pharmacy, Santa Cruz 2009
- Fourth Conference of Oncology Pharmacy, Jahuel 2011
- Fifth Conference of Oncology Pharmacy, Huilo - Huilo 2013
- Sixth Conference of Oncology Pharmacy, Reñaca 2015

CQFO has also organized 14 concurrent sessions of oncology pharmacy in the congresses of the Sociedad Chilena de Cancerología, Sociedad Chilena de Oncología Médica, Sociedad Chilena de Mastología, Simposio Latinoamericano de Gastroenterología (SLAGO) and Simposio Latinoamericano de Urología Oncológica (SLAURO).

With Chile, being the first Latin American country chosen as the location of an ISOPP Symposium, CQFO has the honor to be the host organization of such an important international meeting.

Become a Member
You can become a member of CQFO if you: are a Pharmacist; work in the field of oncology pharmacy; are recommended by two active members; and pay your annual membership fees.

Membership benefits include: support in continuing education; access to scholarships for different activities such as workshops, symposia and congress of oncology; and access to periodic scientific talks for members.

Association Contact Information
For information about the CQFO, membership or services, email farmaceuticos.oncologia@gmail.com or get in contact via twitter @QF_oncologia.
Committee Listings

Thank you to the ISOPP 2016 Planning Committee members, the Scientific Program Committee members, the Local Committee members and the ISOPP Secretariat and Chairs for their work in planning this Symposium. We would also like to thank those who have volunteered their time to assist the ISOPP 2016 participants and organizers. We really appreciate the assistance you provide to ensure participants have everything they need to participate effectively in the Symposium.

Planning Committee

Alejandra Barahona, Symposium Chair, Hospital del Salvador, Santiago, Chile
Sulamita Miranda Nam, Scientific Program Committee Co-Chair, Andrés Bello University, Santiago, Chile
Alexandre Chan, Scientific Program Committee Co-Chair, National University of Singapore, Singapore
Gustavo Espinoza, Central de preparaciones oncológicas REDSANA, Santiago, Chile
Laura Garcia, Centro de Especialidades Farmacéuticas, Santiago, Chile
Steve Stricker, Takeda Oncology, Florence, KY, USA
Sea to Sky Meeting Management, North Vancouver, BC, Canada

Scientific Program Committee

Alejandra Barahona, Hospital del Salvador, Santiago, Chile
Sulamita Miranda Nam, Andrés Bello University, Santiago, Chile
Alexandre Chan, National University of Singapore, Singapore
Sara Aguayo, Hospital Base San José Osorno, Osorno, Chile
Asunción Albert Mari, Hospital Universitario y Politécnico La Fe Avda Fernando Abril Martorell, Valencia, Spain
Teresa Aqueveque, Hospital Regional de Talca, Talca, Chile
Peter Gilbar, Toowoomba Hospital, Toowoomba, Australia
Evelyn Handel, National Comprehensive Cancer Network, Ambler, PA, USA
Tara Leslie, Tom Baker Cancer Centre and University of Alberta, Calgary, AB, Canada
Annemerí Livinalli, Sociedade Brasileira de Farmacêuticos em Oncologia, São Paulo, Brazil
Betzábel Rubio, Facultad de Ciencias Químicas y Farmacéuticas Universidad de Chile, Santiago, Chile
Claudia Schramm, Hospital Base Valdivia, Valdivia, Chile
Rosalyn Sims, Children’s Hospital of Michigan, Troy, MI, USA
Judith Smith, The University of Texas Health Science Center at Houston Medical School, Houston, TX, USA
Shinya Suzuki, National Cancer Center Hospital East, Kashiwa, Japan
Local Committee
Alejandra Barahona, Hospital del Salvador, Santiago, Chile
Sulamita Miranda Nam, Andrés Bello University, Santiago, Chile
Sara Aguayo, Hospital Base San José Osorno, Osorno, Chile
Teresa Aqueveque, Hospital Regional de Talca, Talca, Chile
Gustavo Espinoza, Central de preparaciones oncológicas REDSANA, Santiago, Chile
Laura García, Centro de Especialidades Farmacéuticas, Santiago, Chile
Monica Jeria Castro, Hospital Clínico Universidad De Chile, Santiago, Chile
Jorge Morales Vallespín, Hospital Dr. Luis Calvo Mackenna, Santiago, Chile
Betzabé Rubio, Facultad de Ciencias Químicas y Farmacéuticas Universidad de Chile, Santiago, Chile
Claudia Schramm, Hospital Base Valdivia, Valdivia, Chile

ISOPP Secretariat and Chairs
Rowena Schwartz, President, McKesson Specialty Health, The Woodlands, TX, USA
Harbans Dhillon, President-Elect, University Malaya Medical Centre, Kuala Lumpur, Malaysia
John Wiernikowski, Secretary, McMaster Children’s Hospital, Hamilton, ON, Canada
Johan Vandenbroucke, Treasurer, Ghent University Hospital, Ghent, Belgium
Tiene Bauters, General Member, Ghent University Hospital, Ghent, Belgium
Evelyn Handel, General Member, National Comprehensive Cancer Network, Ambler, PA, USA
Anantha Naik Nagappa, General Member, Manipal College of Pharmaceutical Sciences, Manipal, India
Shaun O’Connor, General Member, Box Hill Hospital (Eastern Health), Box Hill, VIC, Australia
Alexandre Chan, Education Chair, National University of Singapore, Singapore
Jill Davis, Newsletter Editor, Melbourne, Australia
Felice Musicco, Publications Chair, Istituti Fisioterapici Ospitalieri, Rome, Italy
Judith Smith, Research Chair, The University of Texas Health Science Center at Houston Medical School, Houston, TX, USA

CQFO Executive Committee and Directors
Alejandra Barahona, President, Hospital del Salvador, Santiago, Chile
Laura García, Vice President, Centro de Especialidades Farmacéuticas, Santiago, Chile
Magaly Santander, Treasurer, Instituto Nacional de Cancer, Santiago, Chile
Gustavo Espinoza, Secretary General, Central de preparaciones oncológicas REDSANA, Santiago, Chile
Sara Aguayo, Hospital Base San José Osorno, Osorno, Chile
Teresa Aqueveque, Hospital Regional de Talca, Talca, Chile
Rose Marie Fresard, Hospital del Salvador, Santiago, Chile
Alejandra Rodríguez, Clínica Sanatoria Aleman, Concepción, Chile
Betzabé Rubio, Facultad de Ciencias Químicas y Farmacéuticas Universidad de Chile, Santiago, Chile
Claudia Schramm, Hospital Base Valdivia, Valdivia, Chile
Jorge Morales Vallespín, Hospital Dr. Luis Calvo Mackenna, Santiago, Chile
Symposium Information
Hotel Facilities and Services

Venue Address and Contact Information
Sheraton Santiago Hotel
Ava Santa Maria 1742, Santiago, Chile
Telephone: +56-2-2233-5000
sheraton.com/santiago

Business Centre
For internet access, photocopying, and other business needs, the hotel's business centre is located on Z Level (Lower Level) and the business hours are Monday to Saturday, 09:00 to 17:00.

First Aid / Emergency
For first aid assistance or in case of a medical emergency, ask any hotel staff or the Symposium Registration staff for help. For emergency or non critical care, the Indisa Hospital is located one block from the Sheraton Santiago on Ava Santa Maria 1810. The telephone number is +56-2-2362-5555.

Information
Please ask at the hotel's concierge desk for information on the closest restaurants, lost and found and other guest services. The concierge desk is open 24 hours. The nearest ATM is located on Z Level (Lower Level), near the Sheraton Santiago elevators.

Internet Access
Complimentary wireless internet is available in guest rooms. If you are a guest of the hotel, and you can also access wireless internet in the meeting space. Depending on how many attendees use the wireless internet, speed may be slow. If you require a fast connection, please enquire at the Business Centre.

Lost and Found
For assistance with lost and found items, please see the hotel concierge who will be able to contact the house keeping and security departments who keep track of all lost and found items.

Smoking
Smoking is not permitted during the Symposium sessions or anywhere inside the hotel. Smoking is permitted in the pool and garden areas.
Conference Administration and Services

Catering and Dietary Requirements

Lunches and refreshment breaks will be held in the Exhibit and Poster Hall in San Cristobal on the Lobby Level. The refreshment break on Wednesday afternoon will be held at the concurrent session rooms.

In addition, lunch will be provided by the sponsors of the satellite symposia taking place at lunch time.

Dietary requirements provided during online registration have been communicated to the hotel. If special meals are being provided for you, you will receive dietary tickets with your name badge. If you have dietary requirements and did not let us know during the registration process, please inform the staff at the Registration Desk.

Certificate of Attendance

If you requested a Certificate of Attendance during the registration process, it will be emailed to you after the Symposium.

Liability and Disclaimer

Participants take part in the ISOPP 2016 Symposium at their own risk.

Name Badges

In addition to being a means of identification for your fellow participants, name badges must be worn at all times and are required to enter sessions and functions. If you misplace your name badge, please visit the Registration Desk to request a new one.

Registration Location and Hours

The Registration Desk is located in the Foyer on the Lobby Level and is open during the following hours:

- Sunday, April 17: 12:00 – 18:30
- Monday, April 18: 08:00 – 16:30
- Tuesday, April 19: 08:30 – 16:30
- Wednesday, April 20: 08:30 – 17:00

Session Protocol

The language of the Symposium is English.

Every effort will be made to ensure that all sessions start and end on time. Speakers and participants are asked to work together to respect the Symposium schedule.

Respect your fellow participants by turning cellular phones, pagers and other noise-making devices on mute during the sessions.

Simultaneous Interpretation

Simultaneous Interpretation from English to Spanish is provided during plenary and panel sessions in Pedro de Valdivia AB and concurrent sessions in Pedro de Valdivia C and El Quixote. Simultaneous Interpretation from Spanish to English is provided for the Roche Satellite Symposium. Sessions with Simultaneous Interpretation are indicated with this symbol. 

#ISOPP2016

Page 33

isopp2016.org
Social Event Tickets

The Welcome Reception takes place on Sunday, April 17 from 17:15 to 18:30 amongst the Exhibits and Posters in the Exhibit and Poster Hall in San Cristobal on the Lobby Level. The event is sponsored by Roche Chile. The “Explore ISOPP Opportunities” Reception takes place on Tuesday, April 19 from 17:45 to 18:30 in the San Cristobal Foyer. All Symposium participants are welcome to attend these events and a ticket for admission is not required.

The Tuesday evening social event, ISOPP 20th Anniversary Dinner Chilean Style, takes place from 19:30 to 23:00 in Pedro de Valdivia AB. If included in your registration category, your ticket was provided to you in your name badge. Guest tickets may still be available at 150 Euro. If you would like to buy (an) additional ticket(s), visit the Registration Desk.

Symposium Survey

Shortly after the Symposium, you will receive an email with a link to the Symposium survey where you can give us your feedback on all aspects of your experience at the Symposium. Your feedback is important to us and we rely on this information to help us improve future ISOPP Symposia. Please take a few minutes to complete the survey. The survey is sponsored by Fresenius Kabi.

Tour Bookings

Please see the Turistik desk in the Lobby for information on Santiago tours and excursions. Information on selected Daily Tours and Pre & Post Tours is also available on the ISOPP 2016 website.
Symposium Program Details

Sunday, April 17

Pre-Symposium Workshop
09:00-12:30  (Pedro de Valdivia C)  This session will be presented in Spanish with some English.

The Pre-Symposium Workshop aims to update the basic concepts in oncology pharmacy practice. The following topics will be covered: (1) pharmacogenomics and pharmacokinetics of anticancer therapies, (2) management of major adverse events associated with chemotherapy and (3) updates on safe handling of cytotoxics.

Opening Ceremonies
Rowena Schwartz, ISOPP President, McKesson Specialty Health, The Woodlands, TX, USA
Alejandra Barahona, CQFO President, Hospital del Salvador, Santiago, Chile
Sulamita Miranda Nam, Scientific Program Committee Co-Chair, Andrés Bello University, Santiago, Chile
Alexandre Chan, Scientific Program Committee Co-Chair, National University of Singapore, Singapore
15:00 – 16:15  (Pedro de Valdivia AB)

Opening Plenary
Access to Cancer Medicines: Global Disparities Deserve Global Attention
Julie Torode, Union for International Cancer Control (UICC), Geneva, Switzerland
16:15 – 17:15  (Pedro de Valdivia AB)

Cancer is composed of a complex set of heterogeneous diseases which require very different and multidisciplinary approaches to assure optimal outcomes for patients. With our improving understanding of the molecular characteristics of cancer and an increasing array of tools to intervene, most patients today can expect to benefit from clinical intervention – whether achieving long-term remission, cure, or palliation. However, this progress is predicated on the assumption that cancer patients have routine and continuous access to quality affordable cancer medicines.

In recent years the global health community has begun to focus its attention on Non-communicable Diseases (NCDs) – including cancer - as evidence of the current global epidemic has grown. Following the UN High Level Meeting on NCDs in 2011, the World Health Organization (WHO) developed its Global Access Plan on the Prevention and Control of NCDs. Supported by a resolution on Access to Essential Medicines, adopted by WHO in 2014, this Plan calls for – among other targets – an 80% availability of affordable, basic technologies and essential medicines by 2025, including those for cancer.

In spite of commitments of all governments around the world to this global inspirational goal on access and emerging discussions on universal health coverage, many under-resourced countries lack the bandwidth to develop national cancer formularies and address the complex web of barriers and challenges to implement the necessary infrastructure and processes at a national level. Recognising more than 60% of the world's total cases of cancers occur in Africa, Asia, and Central and South America, and these regions already account for approximately 70% of the world's cancer deaths, UICC advocates for urgent attention to address the global disparity in availability and access to cancer treatment and care services as well as rational selection of cancer medicines aligned with national needs.

Learning Objectives:
- Give an overview of UN process that have put access on the global health agenda;
- Introduce UICCs work on essential cancer medicines which provided the basis of updates adopted in the new 2015 WHO Model List of Essential Medicines;
• Consider the role of the WHO Model List of Essential Medicines as a first step in stimulating national action and access to life-saving cancer treatment services; and
• Discuss additional barriers and challenges such as regulatory and distribution hurdles and opportunities for ISOPP to bring expertise and engagement to achieve the 80% by 2025 target.

Welcome Reception
Sponsored by Roche Chile
17:15 – 18:30 (Exhibit and Poster Hall, San Cristobal)

The Welcome Reception will take place amongst the exhibits and posters. Come and meet the Symposium sponsors and exhibitors, poster presenters and many of your peers in a casual atmosphere! Participation is included in your registration fee.

Monday, April 18

Plenary

Novel Immunotherapy for Melanoma: Mechanisms, Outcomes, and Future Strategies
R. Donald Harvey, Winship Cancer Institute of Emory University, Atlanta, GA, USA
09:00 – 09:45 (Pedro de Valdivia AB)

Therapeutic antibodies that block the programmed cell death protein-1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) immune checkpoint pathways prevent T-cell downregulation and promote immune responses against a number of cancer types, with melanoma being the prototype disease for initial investigation of single agent and combination strategies. The US FDA has approved ipilimumab, nivolumab, and pembrolizumab for advanced melanoma, and additional investigations are ongoing. This session will review the pharmacology, clinical trial and adverse event data, and potential future of agents that block CTLA-4, PD-1 or its ligands, and novel pathways (e.g., CSF-1R, OX40) as melanoma and anticancer therapy.

Learning Objectives:
• Distinguish between the indicated uses, mechanisms of action, depth and duration of clinical responses, and safety of current and emerging immunotherapeutic targeted agents;
• Outline a treatment plan for newly diagnosed melanoma patients to achieve the deepest and most durable response while balancing the risk for adverse events; and
• Describe emerging pathways and potential targets for the next generation of immunotherapy.

Refreshment Break
09:45 – 10:15 (Exhibit and Poster Hall, San Cristobal)
Plenary
Clinical Impact and Recent Outcomes of Immunotherapy in Solid Tumours: Is it the Pathway for Cancer Cure?
Christian Caglevic, Fundación Arturo López Pérez, Santiago, Chile
10:15 -11:00 (Pedro de Valdivia AB)
The lecture will address principles of immunotherapy and cancer and the current treatment options for cancer patients.
Learning Objectives:
• Show the main mechanisms of immunotherapy in cancer pathogenesis and treatment;
• Describe the principles of use and toxicities related with immunotherapy drugs; and
• Show the development of the main immunotherapy and their outcomes in cancer treatment.

Concurrent Sessions 1

Clinical 1A: Solid Tumor Updates
11:00 - 12:00 (Pedro de Valdivia C)

Solid Tumor Update: Lung Cancer
Evelyn Handel, National Comprehensive Cancer Network (NCCN), Ambler, PA, USA
The treatment options for patients with lung cancer have greatly expanded as a result of advances in immunotherapy and targeted therapy. This presentation will briefly review the molecular biology and subtypes of lung cancer and then describe how the new therapeutic approvals and indications for medications used to treat lung cancer fit in among previous therapies. The clinical data for new agents as well as updated guideline recommendations in the treatment of lung cancer will also be discussed. Lastly, emerging data on investigational agents and therapeutic approaches with potential importance in the treatment of patients with lung cancer will also be reviewed.
Learning Objectives:
• Briefly review the molecular biology and different subtypes of lung cancer;
• Describe the clinical data and rationale for new therapeutic approvals/indications and updated guideline recommendations in the treatment of lung cancer; and
• Discuss emerging data on investigational agents and therapeutic approaches with potential importance in the treatment of patients with lung cancer.

Solid Tumor Update: Breast Cancer
Kellie Jones Weddle, Purdue University, Indianapolis, IN, USA
Breast cancer treatments are constantly evolving. As clinicians understand the biology of the disease better, unique targeted therapies are created. In this presentation, we will review the use of the HER-2 targeted therapies and how this landscape has changed. We will also discuss the role of pertuzumab in both the neoadjuvant and metastatic settings. Newer therapies have been approved for use in hormone positive patients. We will review the data with palbociclib in the metastatic setting and discuss its role in therapy. Lastly, we will review updated changes to the breast cancer screening guidelines.
Learning Objectives:
• Discuss the role of pertuzumab in the metastatic and neoadjuvant settings;
• Review the use of Her2 targeted therapies in early and late stage breast cancer;
• Evaluate the role of palbociclib in hormone receptor positive breast cancer; and
• Discuss the changes in the breast cancer screening guidelines in the United States.
Research 1B: Research with Complementary Alternative Medications in Oncology
11:00 – 12:00 (El Quixote)

Judith Smith, The University of Texas Health Science Center at Houston Medical School, Houston, TX, USA

The session will discuss the use of complementary alternative medications (CAM) including herbal, nutritional, vitamin and mineral supplement in the oncology arena. Briefly we will review the data demonstrating the benefits of CAM agents for both cancer prevention and treatment focusing potential to improve patient outcomes. Updates on how to evaluate the literature and identifying resources to assist in identifying and preventing potential supplement-chemotherapy interactions will be reviewed.

Learning Objectives:

• Identify herbal and nutritional supplements that have been associated with the prevention or treatment of various cancers;
• Evaluate the use of herbal and nutritional supplements in the treatment of treatment-related side effects based upon a review of the literature presented; and
• Critique the use of herbal and nutritional supplements as either a direct or indirect interaction with chemotherapy, radiation or surgical interventions for cancer.

Concurrent Sessions 2

Clinical 2A: Antiemetic Updates
12:00 – 13:00 (Pedro de Valdivia C)

Antiemetic Update: Olanzapine
Alexandre Chan, National University of Singapore, Singapore

Prevention and control of Chemotherapy-induced nausea and vomiting (CINV) are paramount in the management of patients with cancer. Olanzapine, which is an atypical antipsychotic, has gained a lot of attention within the area of cancer supportive care as it is able to block multiple receptors that are implicated in the pathogenesis of CINV. In this session, we will review the mechanism of action of olanzapine and discuss its implication for CINV management. We will also review the emerging data that suggest olanzapine’s role for preventing CINV and treatment of breakthrough and refractory CINV. Lastly, we will discuss the current guideline recommendations on olanzapine for CINV management.

Learning Objectives:

• Understand the mechanism of action of olanzapine and its implication on CINV management;
• Review the evidence for treating refractory and breakthrough CINV with olanzapine;
• Review the evidence for preventing CINV with olanzapine; and
• Discuss the current guideline recommendations on olanzapine for CINV management.

Antiemetic Update: New NK1 Antagonists
Ivonne Flores, Fundación Arturo López Pérez, Chile

Nausea and vomiting are the main and most common side effects of chemotherapy. Introduction of aprepitant, the first NK1 antagonist, to the combination of antagonists of the 5-HT3 and dexamethasone, has been for years the standard prophylaxis for highly emetogenic chemotherapy. New NK1 antagonists, their mechanisms of action and their relationship to the pathways involved in emesis will be reviewed in this session. In addition, the current recommendations of the clinical guidelines of antiemetic therapy in relation to the NK1 antagonists will be review.
Learning Objectives:

- Learn the history of the development of NK1 antagonists;
- Review current NK1 antagonist agents;
- Understand the mechanism of action of NK1 antagonists and their relationship with other drugs involved in the management of nausea and vomiting induced by chemotherapy; and
- Review current recommendations of antiemetic treatment guidelines in relation to the NK1 antagonists.

Fundamental 2B: Pharmacovigilance Plan for Biologics and Biosimilar Antibodies: Is it Really Useful?
12:00 – 13:00 (El Quixote)
Alan Astier, Henri Mondor University Hospitals, Créteil, France

A major event today and for the next years, is that many medications such as monoclonal antibodies (e.g. trastuzumab and rituximab) are no longer subject to patent restrictions. Considering the very high cost of these biologics, judicious use of biosimilars are of paramount importance to lower expenses and to permit their wider access to patients, especially in developing countries. However, strong opposition against biosimilars remain.

It is important for pharmacists to understand that biosimilars can be now fully described and characterized from a physico-chemical point of view. Particularly, the aggregation profile can be deeply analyzed. Micron-size aggregates are also responsible for unwanted immunological side-effects. These aspects will be discussed in detail during the presentation.

Thus, long-term pharmacovigilance plan are required to detect any differences in the tolerance profile of biosimilars.

Learning Objectives:

- Describe major methods to characterize biosimilars;
- Understand the role of aggregation in the side-effects of biologics; and
- Discuss the interest of a post-market authorization pharmacovigilance plan.

Research 2C: Epigenetic Bases of Gastric Cancer: From Pathogenesis to the Potential Identification of New Targets for Prevention and Treatment
12:00 – 13:00 (O’Higgins)
Alejandro Corvalán, Pontificia Universidad Católica de Chile, Santiago, Chile

Gastric cancer is the fifth most common cancer and the third leading cause of cancer-related death. The low-abundance of mutations on comprehensive molecular evaluation of primary tumors suggests that other mechanisms contribute to this disease. For example, epigenetic alterations including DNA methylation of promoter sites, short and long noncoding RNAs and histone modifications ultimately control gene expression. This presentation aims to elaborate on the role of epigenetics in the pathogenesis of gastric cancer and the potential identification of new targets for prevention and treatment of disease based exclusively on epigenetic alterations.

Learning Objectives:

- Review Gastric Cancer;
- Understand Genetic and Epigenetic bases of gastric cancer; and
- Discuss Translational epigenetic research in diagnosis and treatment on gastric cancer.
Biological and Biosimilars: Pharmacovigilance, Interchangeability and Extrapolation of Indications/
Biológicos y Biosimilars: farmacovigilancia, intercambiabilidad y extrapolación de indicaciones
Renato Murillo, Profesor Caedrático, Universidad de Costa Rica, Cost Rica

This session will be presented in Spanish with Simultaneous Interpretation into English.

Biological drugs produced by recombinant DNA technologies have the peculiarity that the final structure is
dependent on the production process and its development; among other things, its complexity exceeds thousand
times the complexity of small molecules. Creating a copy of these drugs is, according to current technologies,
impossible. That is why non-innovative versions of these drugs may be similar to their reference products, but not
equal. These versions are called biosimilars.

This has led to differences in regulations for the development of biosimilars from generics and there are several
factors to consider: not being equal to innovative versions, pharmacovigilance programs should be more stringent
in order to assess adverse drug reactions that can occur and have not been presented in the innovator product,
and even the percentage of incidence of the known adverse reactions; In view of this, interchangeability between
an innovative product and a biosimilar can interrupt the pharmacovigilance program and an erroneous adjudication
of adverse reactions; moreover, as recently reported, this interchangeability could induce increased one of the most
important adverse reactions of such products: immunogenicity.

Taking in consideration that many biological products have more than one therapeutic indication, international
guidelines allow for evaluation and clinical extrapolation if several conditions are met (the studied indication should
have the most sensitive population and mechanism action must be the same, for example). When these conditions
are not met, extrapolation of indications is not recommended and this leads to other consequences. Such as
the case of the medical indication by the use of the International Non-Proprietary Name (INN), this could lead to
confusion to know which drug (the innovator or biosimilar) should be administered to the patient, if the indication
is not approved for the biosimilar. In addition to the consequences that this would lead to the pharmacovigilance
program.
Treatment of patients with ALL is generally classified into different phases: induction, early intensification, consolidation, re-induction and maintenance, showing remission rates close to 90%. In these phases of the protocol, patients receive different types of antineoplastic drugs, highlighting the 6-mercaptopurine (6-MP) in oral therapy, being present in 3 of the 5 stages of treatment.

Although 6-MP plays a pivotal role in treatment, it is not without side effects, and these effects are much increased in patients with single nucleotide polymorphism in genes coding for 6-MP metabolizing enzymes such as TPMT and ITPA. Therefore, it is important to detect and incorporate pharmacotherapeutic monitoring in this group of patients.

Learning Objectives:
- Introduce the PINDA program for the treatment of acute lymphoblastic leukemia in pediatrics in Chile;
- Evaluate the clinical monitoring tools for patients with acute lymphoblastic leukemia in Chile;
- Establish a connection between certain genotypes coding for the enzyme TPMT and adverse effects during therapy of acute lymphoblastic leukemia (RAM reports and prevalence in patients at follow-up);
- Determine the most effective pharmacotherapy based on genotype frequency; and
- Evaluate and adhere to treatment guidelines: Mercaptopurine dose changes according to polymorphism results and according to pharmaceutical care.

Update on Paediatric Bone Tumours
John Wiernikowski, McMaster Children’s Hospital, Hamilton, ON, Canada

Bone tumours in children are comprised primarily of Osteogenic Sarcoma and Ewings Sarcoma which is often subcategorized as Osseous, Extra-Osseous and Primitive neuroectodermal tumours. The annual incidence of these tumours are on the order of 4 and 3 cases per million respectively, but show considerable geographic variability.

Despite aggressive management with chemotherapy, surgery and (for Ewings sarcomas) radiation; 5 yr EFS rates range from 60-70% for children and adolescents with localized disease, and only 20-25% for those with metastatic disease at diagnosis.

Recently, advances in molecular biology of these tumours has identified a host of new targets including Tyrosine Kinases, IGFR-1, m-TOR, EWS-FLI-1 and targetable pathways that offer the promise of better outcomes for this patient population. This talk will review and update the data on these new molecular targets and available clinical trial data.

Learning Objectives:
- Be able to distinguish between Osteogenic and Ewing’s Sarcomas and appreciate the geographic variability in incidence of these entities;
- Appreciate the various treatment modalities utilized in the treatment of bone tumours;
- Understand newly identified molecular targets in these disease entities and drugs currently be evaluated in clinical trials; and
- Appreciate approaches to global co-operation in clinical trial execution that are accelerating accrual of patients to these trials.
Fundamental 3B: USP 800 Implementation and Practical Considerations
14:30 – 16:00  (El Quixote)

USP 800 Implementation: Considerations Across Practice Settings
Rowena Schwartz, McKesson Specialty Health, The Woodlands, TX, USA

The recent USP 800 guideline updates have been published and are widely being evaluated around the world. During this presentation we will discuss the guidelines, and the practicalities of implementing these recommendations in a variety of practice settings in the United States.

Learning Objectives:
• Recognize and share the problems with implementing the USP 800 in other countries;
• Understand how to implement the USP 800 in other countries; and
• Share the experience and ideas learned when we implement the USP 800.

USP 800 Implementation: Consider a Case of the National Cancer Center Hospital East, Japan
Shinya Suzuki, National Cancer Center Hospital East, Kashiwa, Japan

Recently, the first guideline for handling hazardous cancer agents, “JSCN/JSMO/JASPO Joint Guidelines for Safe Handling of Cancer Chemotherapy Drugs 2015” has been established in Japan. (*JSCN: Japanese Society of Cancer Nursing, JSMO: Japanese Society of Medical Oncology, JASPO: Japanese Society of Pharmaceutical Oncology) The JASPO played an important role in creating this guideline, and the National Cancer Center Hospital East (NCCHE) is one of the leading institutions that will conduct projects to prevent exposure of hazardous medicines. When we made the guideline, we realized many real world discrepancies between ideal management and daily practice management within a hospital. At NCCHE, we encountered some problems when implementing the international guidelines, such as the USP 800, which is one of the core ideas to perform safe handling of hazardous medicine. In the session, I will share ideas and tips on how to implement the USP 800 for the non-US countries through our experience at the NCCHE in Japan.

Learning Objectives:
• Recognize and share the problems with implementing the USP 800 in other countries;
• Understand how to implement the USP 800 in other countries; and
• Share the experience and ideas learned when we implement the USP 800.

Fundamental 3C: Education, Competency and Mentorship
14:30 – 16:00  (O’Higgins)

Judith Smith, The University of Texas Health Science Center at Houston Medical School, Houston, TX, USA
Barry Goldspiel, National Institutes of Health Clinical Center, Bethesda, MD, USA

This session will discuss how the three topics of education, competency and mentorship are related. The first part of the didactic lecture will provide key elements and tools to be used for chemotherapy education and tools for the “peripheral brain” reminders. Examples and electronic copies (bring your own jump drive) will be provided for audience to take home and implement. This will transition how and why oncology pharmacy can take the lead in establishing chemotherapy competency programs for the multidisciplinary team. Finally, this session will discuss the role of mentorship throughout professional development across lifespan. Real-life scenarios will be provided to help role model successful mentorship and how it is a key ingredient in professional development.
Learning Objectives:

- Compare and contrast education tools to assist in chemotherapy order process;
- Explain how Oncology Pharmacy can lead efforts to establish multidisciplinary chemotherapy competency;
- Develop an action plan for identifying a mentor; and
- Describe different approaches for requesting mentorship from others.

Refreshment Break
16:00–16:30 (Exhibit and Poster Hall, San Cristobal)

Concurrent Sessions 4

Fundamental 4A: Oral Medication Adherence and Management in Oncology
16:30 – 18:00 (Pedro de Valdivia C)

Oral Medication Adherence and Management in Oncology
Steve Stricker, Takeda Oncology, Florence, KY, USA

As the global focus of drug development shifts from injectable to oral routes of administration, the responsibility for successful completion of the prescribed treatment regimen shifts from the infusion center to the patient and their caregivers. This paradigm shift for cancer therapy introduces new challenges for health care providers responsible for the management of patients with cancer. In this presentation, we will discuss challenges and barriers to oral medication adherence; methods for improving oral medication adherence; and clinical pearls related to the education and management of oral oncolytics.

Learning Objectives:

- Discuss the current status of approved and investigational oral oncolytics;
- Identify challenges with the use of oral oncolytics and common causes of nonadherence;
- Review opportunities and methods for pharmacists to improve adherence with oral oncolytics; and
- Discuss clinical pearls related to education and management of oral oncolytics in clinical practice.

Strategies to Improve Oral Medication Adherence in Oncology
Harbans Dhillon, University Malaya Medical Centre, Kuala Lumpur, Malaysia

Increasingly the delivery of chemotherapy has changed from an inpatient to an outpatient model and many oral therapies are managed in the patient’s home environment. Adherence rates impact dosing, adverse events and ultimately, overall survival. The World Health Organization has cited the issue of non-adherence with oral chemotherapy as the single most important yet modifiable factor that can compromise treatment outcomes.

In this presentation, several interventions to improve adherence to oral chemotherapy will be discussed. Maximizing adherence to oral chemotherapy agents can improve overall survival and life expectancy; improved safety and quality of life. Patients risk improper dosing and an increase in disease recurrence when there is non-adherence with medications. Correct dosing, education and symptom management are all critical to ensuring adherence. Other interventions incorporate education, early symptom identification and reminder prompts to improve adherence.
Learning Objectives:

- Identify interventions to improve adherence to oral chemotherapy;
- Identify risks to patients on non-adherence; and
- Incorporating patient education and reminder prompts as part of counseling to improve adherence to oral chemotherapy.

**Research 4B: Investigational Agents Update**

16:30 – 18:00 *(El Quixote)*

Rowena Schwartz, *McKesson Specialty Health, The Woodlands, TX, USA*
R. Donald Harvey, *Winship Cancer Institute of Emory University, Atlanta, GA, USA*

One of the most exciting aspects of cancer care is the rapid evolution of drug therapy. In the last five years we have seen the development of new agents, many first in class, and subsequent new applications of those agents. This rapid evolution of new anticancer drugs should be coupled with the practical challenges of successfully implementing these therapies into cancer care beyond the clinical trial. New mechanisms of actions may be associated with unique treatment related toxicities, which may require innovative approaches to care. During this session we will focus on drugs and drug classes that are currently being evaluated in clinical trials and discuss the role of the oncology pharmacist in optimizing care with these agents.

Learning Objectives:

- Identify potential applications for the investigational agents discussed during this session;
- Describe proposed mechanism of action and toxicities associated with the drugs discussed; and
- Provide healthcare team and patient and caregiver team education about drugs discussed.

**Clinical 4C: Oncology Patients and Special Circumstances**

16:30 – 18:00 *(O’Higgins)*

**Incidence of Drug-Induced Liver Injury in Patients Hospitalized at The Instituto Nacional de Enfermedades Neoplasticas Lima**

Martha Estacio, *Instituto Nacional de Enfermedades Neoplasticas Eduardo Caceres Graziani, Lima, Peru*

The actual incidence of drugs that cause liver damage in clinical practice is poorly understood. The international incidence in hospitalized patients is 0.7% to 1.4%. Most are idiosyncratic or of unexpected origin. The main mechanism is the generation of reactive metabolites produced in Phase I metabolism. The final outcome varies from a delay in treatment to liver failure or death.

The diagnosis of hepatic adverse reactions in cancer patients remains a challenge due to the complexity of drug therapy, opportunistic infections, radiotherapy, pre-existing liver disease and genetic susceptibility.

Learning Objectives:

- Identify the incidence of drug-induced liver injury in patients hospitalized at the Instituto Nacional de Enfermedades Neoplasticas Lima; and
- Determine medications that cause liver damage.

**Cancer in Pregnancy**

Peter Gilbar, *Toowoomba Hospital, Toowoomba, Australia*

Cancer in pregnancy occurs rarely with an estimated incidence of one in 1,000 pregnancies. The most common malignancies in gestation are breast and cervical cancers, lymphoma, leukemia and melanoma. Diagnosis is often
delayed as symptoms and physical signs of malignancy may be masked by those of pregnancy. Clinicians are faced with the challenge of providing the mother with the best options for treatment while ensuring the safety of the unborn child.

The risks of systemic antineoplastic treatment (cytotoxic, endocrine, targeted agents and immunotherapy) administration during pregnancy depend on the drugs used and the gestational age of the fetus. During the period of organogenesis, chemotherapy administration carries an increased risk of fetal malformation and spontaneous abortion. The risk of malformations is significantly reduced in the second and third trimesters but chemotherapy can cause intrauterine growth retardation, pre-maturity and low birth weight. Administration of chemotherapy within 3 weeks of anticipated delivery is not recommended to avoid neonatal myelosuppression and potential complications like bleeding and sepsis. If chemotherapy is indicated, unless delivery can be accomplished within a few weeks of diagnosis, treatment should be instituted during pregnancy rather than waiting until after delivery.

Information on the effects of antineoplastic drugs given during pregnancy is limited and has largely been derived from case reports and small case series. Most existing data is from older drugs such as the anthracyclines, with little information available on newer agents including monoclonal antibodies or targeted therapies. Breast cancer in pregnancy should be treated similarly to that in non-pregnant patients except that chemotherapy is delayed until the second trimester. Hematologic malignancies are also treated in the same way.

Learning Objectives:

• Understand the process for diagnosis of cancer in pregnancy;
• Recognize the risks associated with the use of systemic treatments in pregnancy;
• Understand which antineoplastic agents and supportive therapies are safe for use during pregnancy; and
• Appreciate the specific management of some of the more common malignancies (e.g. breast, lymphoma) seen in pregnancies.

Tuesday, April 19

Plenary

Dermatologic Toxicities: The Superficial Side of Targeted Therapies

09:00 -10:00  (Pedro de Valdivia AB)

Milan J. Anadkat, Washington University School of Medicine, St. Louis, MO, USA

Systemic therapies (cytotoxic/targeted agents, immune checkpoint inhibitors) have resulted in remarkable improvements in patient survival across all cancers. Despite this remarkable success, the majority of patients treated with these drugs will develop dermatologic adverse events, which lead to decreased quality of life and inconsistent antineoplastic therapy, both of which may affect clinical outcome. This session will provide up-to-date information on dermatologic adverse event incidence, mechanisms, clinical presentation, and preventive/therapeutic interventions. All of which are essential for optimal dermatologic care of people living with cancer.

Learning Objectives:

• Recognize impact on quality of life and clinical characteristics of dermatologic adverse events to therapies in cancer;
• Describe the mechanisms involved in dermatologic adverse events to therapies in cancer; and
• Discuss mechanistically-based interventions to improve quality of life and decrease toxicity in cancer patients.
Concurrent Sessions 5

Clinical 5A: Hematological Cancer Updates
10:30 – 11:30 (Pedro de Valdivia C)

Hematological Cancer Update: Chronic Lymphocytic Leukemia (CLL)
Tara Leslie, Tom Baker Cancer Centre and University of Alberta, Calgary, AB, Canada

Chronic Lymphocytic Leukemia (CLL) is characterized by the progressive accumulation of functionally incompetent monoclonal lymphocytes. Recently, additional treatment options have become available for our CLL patients including those with deletion 17p and those with relapsed or refractory disease.

Learning Objectives:
• Discuss update of recent publications and abstracts for novel agents in CLL;
• Discuss the role of ibrutinib and idelalisib in the management of CLL patients in current clinical practice; and
• Discuss the unique side effect profiles of these agents and a review of patient monitoring recommendations.

Hematological Cancer Updates: Lymphomas
Alexandre Chan, National University of Singapore, Singapore

Lymphomas are a heterogeneous group of malignancies that arise from malignant transformation of immune cells that reside predominantly in lymphoid tissues. Over the past few years, a number of clinical studies as well as novel treatment strategies have evolved the management of certain subtypes of lymphoma. In this session, the speaker will provide a succinct update on these findings.

Learning Objectives:
• Discuss the role of lenalidomide in the management of Non-Hodgkin’s Lymphoma;
• Discuss the novel therapies available for managing mantle cell lymphoma; and
• Discuss the role of immunotherapy in treatment of lymphoma.

Fundamental 5B: Lean Thinking with the Toyota Production System
10:30 – 11:30 (El Quixote)

Shaun O’Connor, Box Hill Hospital (Eastern Health), Box Hill, VIC, Australia

The Toyota Production System (TPS), a collection of tools, strategies and philosophies has been used to improve efficiency and reduce waste in many varied industrial processes, including incrementally in health. Chemotherapy Day Units (CDUs) provide a ripe ground for process improvements aimed at improving the patient experience, with a complex network of staff and data interactions aimed at delivering efficient and safe care for each one of our patients. St Vincent’s Health, Melbourne, supported by Toyota Australia undertook an 18 month long improvement project focusing on the CDU. This presentation will walk through some of the processes and techniques used in this process, highlighting opportunities and pitfalls.
Learning Objectives:

- Gain a basic understanding of terminology and concepts used in TPS and Lean;
- Understand the philosophy and process of a Jishuken improvement event; and
- Understand how some basic elements of TPS can be applied in your workplace.

Clinical 5C: End of Life Care Discussion Session

10:30 – 11:30 (O’Higgins)

Peter Gilbar, Toowoomba Hospital, Toowoomba, Australia
Co-Facilitator: Asunción Albert Mari, Hospital Universitario y Politécnico La Fe Avda Fernando Abril Martorell, Valencia, Spain

Palliative cancer patients in their last months of life are commonly prescribed potentially inappropriate medications. These medications may be for secondary prevention of co-morbid diseases, often have no short-term benefit and may cause potentially harmful effects. In the palliative phase of cancer management, the focus of care should be on the patient’s quality of life, including alleviating suffering from cancer-related symptoms and treating short-term, acute medical illnesses. “Deprescribing” can be defined as the process of withdrawal of an inappropriate medication supervised by health care professionals with the goal of managing polypharmacy and improving outcomes. Deprescribing can benefit patients by reducing the associated costs, potential adverse effects and other burdens of polypharmacy in the last months of life. Guidelines have recently been developed to assist in this process.

Delirium is the most common neuropsychiatric complication seen in patients with advanced cancer. The cause is generally multifactorial involving multiple medical conditions and adverse effects to medications. The management of delirium requires a team approach and involves a combination of non-pharmacologic and pharmacological interventions.

This session will involve a facilitator-led group discussion of issues that may complicate end of life care in cancer patients undergoing palliative treatment. The primary focus will be on deprescribing and the management of delirium but if time permits other neurological symptoms, such as terminal restlessness, may be discussed.

Learning Objectives:

- To understand the concept and benefits of deprescribing unnecessary medications at the end of life;
- To recognise which medications and medication classes may be suitable for discontinuation in palliative patients and to formulate a strategy for deprescribing;
- To appreciate the many potential causes of delirium seen in patients with cancer; and
- To develop strategies for the management of delirium as part of a multi-disciplinary team involving both drug and non-drug approaches.

ISOPP Annual General Meeting

11:30 – 13:00 (Pedro de Valdivia C)

All Symposium participants are welcome to attend and ISOPP members are encouraged to attend the Annual General Meeting.
Satellite Symposium – Merck
Hospital Pharmacists Taking the Lead - How Can Guideline Based Standing Orders / Pathways Enhance Effective CINV Patient Care
13:00 – 14:00 (Pedro de Valdivia AB)
David Warr, Princess Margaret Hospital, Toronto, ON, Canada
Annemeri Livinalli, Sociedade Brasileira de Farmacêuticos em Oncologia, São Paulo, Brazil

13:00 – 13:05 Welcome and Introductions
David Warr

David Warr

13:25 – 13:45 The Pharmacist's Role Establishing CINV Protocols/Formularies
Annemeri Livinalli

13:45 – 14:00 Q&A and Closing Remarks
Faculty

Lunch amongst the Exhibits and Posters
13:00 – 14:30 (Exhibit and Poster Hall, San Cristobal)

Panel
Developing to Established…How to Define Oncology Pharmacy as a Specialty
14:30 – 15:15 (Pedro de Valdivia C)

Panellists: Harbans Dhillon, University Malaya Medical Centre, Kuala Lumpur, Malaysia
Tara Leslie, Tom Baker Cancer Centre and University of Alberta, AB, Canada
Annemeri Livinalli, Sociedade Brasileira de Farmacêuticos em Oncologia, São Paulo, Brazil
Klaus Meier, Heidekreis-Klinikum GmbH, Soltau, Germany
Shaun O’Connor, Box Hill Hospital (Eastern Health), Box Hill, VIC, Australia
Rowena Schwartz, McKesson Specialty Health, The Woodlands, TX, USA
Moderator: Kellie Jones Weddle, Purdue University, Indianapolis, IN, USA

This session will provide various perspectives of how oncology pharmacy has been defined as a specialty. The panel will provide historical and current challenges and solutions for establishing oncology pharmacy specialty as a primary practice.

Learning Objectives:
- Compare and contrast the different roles of oncology pharmacists around the globe;
- Describe the various certifications, licensing, credentials required throughout the world for oncology pharmacy practitioners; and
- Discuss resources and skills required to establish specialty of oncology pharmacy.
Concurrent Sessions 6

Clinical 6A: Supportive Care Updates
15:15 – 16:15 (Pedro de Valdivia C)

Supportive Care Update: Alopecia
Milan J. Anadkat, Washington University School of Medicine, St. Louis, MO, USA

Systemic therapies (cytotoxic/targeted agents) have resulted in remarkable improvements in patient survival across all cancers. Despite this remarkable success, the majority of patients treated with these drugs will develop alopecia and hair changes, which lead to decreased quality of life. This session will provide up-to-date information on alopecia and hair change incidence, mechanisms, clinical presentation, and preventive/therapeutic interventions. All of which is essential for optimal care of people living with cancer.

Learning Objectives:
• Recognize impact on quality of life and clinical characteristics of alopecia and hair changes to therapies in cancer;
• Describe the mechanisms involved in alopecia and hair changes to therapies in cancer; and
• Discuss mechanistically-based interventions to improve quality of life and decrease alopecia and hair changes in cancer patients.

Supportive Care Update: Antibiotic Prophylaxis for Infections
Claudio Gonzalez, Unidad Oncología, Hospital pediátrico Exequiel González Cortés, Santiago, Chile

Chemoprophylaxis is prevention of disease by administration of a drug. In the antibiotic prophylaxis an antimicrobial agent is given to an individual who is at risk of developing an infection because of exposure or an impairment of host defense. Patients with cancer are in a significant risk for infection due to their treatment with chemotherapy, radiation, or surgery. The antimicrobial prophylaxis has a role as preventive strategy in the setting of specific infections. It is very important to know the scientific reasons for indications, dosage and safety of this kind of drugs. In this session, the speaker will provide an update in antibiotic prophylaxis for Infections.

Learning Objectives:
• Discuss the role of antibiotic prophylaxis for infections;
• Review the pharmacokinetic/pharmacodynamic principles in this setting; and
• Describe the safety of this preventive strategy.

Clinical 6B: Bone Marrow Transplant Update
15:15 – 16:15 (El Quixote)

Role of the Clinical Pharmacist in a Stem Cell Transplantation Ward
Tiene Bauters, Ghent University Hospital, Ghent, Belgium

The number of hematopoietic stem cell transplantations (HSCT) has expanded in the last decades and still continues to increase. To ensure safe and effective care in this vulnerable high-risk population, treatment should be undertaken by an experienced and fully dedicated multidisciplinary team.

HSCT pharmacists are well-positioned to take a lead role in patient assessment and development and implementation of guidelines for supportive care.

This presentation aims to give an overview on clinical pharmacy activities in the HSCT setting augmented with examples of routine management for immunosuppression or complications related to HSCT, including participation in ward rounds, analysis of drug-related problems, counseling on discharge medication.
In addition, the pharmacist’s role in the development and implementation of guidelines on acute and late effects or toxicities and involvement in quality assurance will be discussed.

Learning Objectives:

• Recognize the role of the specialty pharmacist in a HSCT setting as a member of a multidisciplinary team; and
• Define commonly observed complications after HSCT.

Bone Marrow Transplant Update
Pablo Ramirez, Catholic University, Santiago, Chile

Hematopoietic stem cell transplantation has become a standard curative procedure in a number of malignant and non-malignant hematological diseases. Since its beginnings, over a million transplants have been performed worldwide and over 50,000 transplants are performed every year around the world. Several advances including better HLA determination techniques, new kind of donors as haploidentical donors, cord blood expansion and ex vivo T cell manipulation, have increased the donor availability so now virtually every individual in need has a potential donor for transplant. Despite this, there are still some barriers to overcome the limitations of transplant associated specially with mortality due to infections, graft rejection, graft vs host disease (GVHD), drug toxicities and relapses. New developments including better antibiotics, new drugs to better control GVHD and new strategies to decrease disease relapse are under study.

Learning Objectives:

• Briefly review the beginnings of HSCT as a field;
• Identify common transplant indications;
• Describe main sources of hematopoietic stem cells;
• Describe main HCST complications;
• Describe alternative hematopoietic stem cells sources;
• Mention new findings about GVHD pathogenesis and strategies to control it; and
• Describe new strategies to decrease the risk for disease relapse.

Research 6C: How to Write your First Grant
15:15 – 16:15 (O’Higgins)
Judith Smith, The University of Texas Health Science Center at Houston Medical School, Houston, TX, USA
R. Donald Harvey, Winship Cancer Institute of Emory University, Atlanta, GA, USA

Very few of us can get enough information and perspective on how to write a grant. It is definitely more of an ‘art’ than a ‘science’ but this session will discuss the fundamentals necessary to build a solid foundation of skills for writing and submitting peer-reviewed grant applications. This session will highlight many of the elements that the ISOPP Research Committee will look for in the 2016 applications as well as help identify other potential sources for research funding.

Learning Objectives:

• Understand the general points on how to prepare a grant application;
• Be able to list and explain the eight sections of a research plan;
• Understand the key elements for a successful grant application;
• Develop your grant writing skills; and
• Develop a plan for identifying sources for research funding.
Refreshment Break, Poster and Exhibit Viewing Session
16:15 – 18:00 (Exhibit and Poster Hall, San Cristobal)

“Explore ISOPP Opportunities” Reception
17:45 – 18:30 (San Cristobal Foyer)
ISOPP members and colleagues are invited to an informal gathering to discuss opportunities for involvement in ISOPP. This is an opportunity to learn how you can contribute to ISOPP’s mission for the future.

ISOPP 20th Anniversary Dinner Chilean Style
19:30 – 23:00 (Pedro de Valdivia AB)
Come celebrate ISOPP’s 20th anniversary Chilean style. Enjoy good food, wine and local culture with friends, old and new. Performers from the Ballet Folklórico Antumapu, an outstanding artistic dance company dedicated to preserving Chilean folk culture, will perform “Chiliche, Gente de Chile” (“The People of Chile”). They will explore the great geographic and cultural diversity of the Chilean man and woman through music, poetry and dance.
Platform Presentations
09:00 – 10:00  (Pedro de Valdivia AB)

Facilitator: Judith Smith, ISOPP Research Chair, The University of Texas Health Science Center at Houston Medical School, Houston, TX, USA

Implementation of a Robot for the Preparation of Antineoplastic Drugs in the Pharmacy Service
Paz Pacheco, Hospital Universitario Clínico San Carlos, Madrid, Spain

The Frequency of the CYP2C19*17 Allele and Its Effect on Pharmacokinetics of Voriconazole in Pediatric Patients
Natalie Espinoza, Hospital Luis Calvo Mackenna, Santiago, Chile

Cytokine Gene Polymorphism, Plasma Concentration and ‘Chemobrain’: Intricate Relationships in Chemotherapy-Receiving Breast Cancer Patients
Alexandre Chan, National University of Singapore, Singapore

Retrospective Analysis of Anti-allergy Prophylaxis for Infusion Reactions of Cetuximab in 248 Head and Neck Cancer Patients
Shinya Suzuki, National Cancer Center Hospital East, Kashiwa, Japan

Refreshment Break
10:00 – 10:30  (Exhibit and Poster Hall, San Cristobal)

Panel
Global Impact of Cancer Care
10:30 – 11:30  (Pedro de Valdivia AB)

Moderator: John Wiernikowski, McMaster Children’s Hospital, Hamilton, ON, Canada

The Global Health Agenda now includes cancer as a priority. In response, the World Health Organization (WHO) has developed a Global Non Common Disease Action Plan which includes cancer control as a key component. One of the objectives in this action plan is to increase access to medicines and essential technologies in all countries of the world. ISOPP is in preliminary discussion with WHO about potential collaborations. Please join us for this important discussion on how ISOPP and Oncology Pharmacists worldwide can collaborate to improve access to treatment for cancer patients.
Concurrent Sessions 7

Clinical 7A: Optimizing Care in the Older Adult with Cancer
11:30 – 13:00 (Pedro de Valdivia C)
Rowena Schwartz, McKesson Specialty Health, The Woodlands, TX, USA
Annemeri Livinalli, Sociedade Brasileira de Farmacêuticos em Oncologia, São Paulo, Brazil

An essential component of cancer care is the individualization of drug therapy for each patient. Over the last decade there has been increasing emphasis on the consideration of age as we select and implement cancer drug therapy including, but not limited to, chemotherapy. During this session we will discuss the evidence for dose modifications based on age or age-related considerations. In addition, strategies for optimizing anticancer drug therapy will be described including routine toxicity evaluation, education and assessment for the older adult with cancer.

Learning Objectives:
• When given a clinical trial, evaluate the impact of age on drug dosing and dose modifications;
• Outline the aspects of aging that should be considered when determining appropriate cancer treatment for an older adult with cancer; and
• Describe strategies to minimize the impact of treatment-related toxicities for the older adult with cancer including chemotherapy dose modifications, minimization of polypharmacy and routine toxicity assessment and management.

Research 7B: How Pharmacists Can Integrate Research into Daily Oncology Practice
11:30 – 13:00 (El Quixote)
Judith Smith, The University of Texas Health Science Center at Houston Medical School, Houston, TX, USA
Tiene Bauters, Ghent University Hospital, Ghent, Belgium
Rosalyn Sims, Children’s Hospital of Michigan, Troy, MI, USA

It’s the holy grail….to be able to have it all in your oncology pharmacy practice – patient care, educational opportunities (students/trainees) and RESEARCH! There is a spectrum of opportunities for oncology pharmacists to incorporate, participate and contribute to oncology research. This session will present various types of projects, including highlights from previous ISOPP grant recipients, that demonstrate successful stories of how you can integrate research into daily oncology practice to ultimately improve your patient outcomes as well as advance your career development.

Learning Objectives:
• Differentiate the potential opportunities for oncology pharmacist to initiate research projects within pharmacy practice;
• Define the characteristics of a good research question; and
• Explain how to identify and utilize resources for research project development and utilization.

Satellite Symposium – BD Medical
Mitigating Risk During Hazardous Drug Handling: Improving the Practice of Safe Handling of Hazardous Drugs
13:00 – 14:30 (Pedro de Valdivia AB)
Johan Vandenbroucke, University Hospital Ghent, Ghent, Belgium

A growing amount of evidence points to the dangers of hazardous drug exposure for healthcare workers during preparation and administration. Many institutions struggle to maximize their safety precautions for a variety of
reasons: lack of awareness of the risks of exposure, the need for more information on engineering controls, lack of international guidelines or enforcement of those guidelines. We anticipate that profound changes on how institutions mitigate hazardous drug exposure will rapidly evolve as individuals become better informed.

This session will review the dangers of hazardous drug exposure, and help to clarify what a closed system drug transfer device (CSTD) is, what organizations have clearly defined as a CSTD, explore the differences in CSTD’s on the market and the important criteria you should consider when selecting one for your institution.

Lunch amongst the Exhibits and Posters
13:00 – 14:30 (Exhibit and Poster Hall, San Cristobal)

Concurrent Sessions 8

Clinical 8A: Application of Pharmacogenomics in Daily Clinical Practice
14:30 – 15:30 (Pedro de Valdivia C)

Mario Chiong Lay, University of Chile and Advanced Center for Chronic Diseases (ACCDiS), Santiago, Chile

In 2001, the release of the draft sequence of the human genome marked a major biological milestone in the human history. Over one and a half decade later, this work continues to shape our biological understanding of normal and disease processes, with enormous implications for public health. During the last 15 years, genome analysis revealed a complete list of genes, genomic structure, and initial descriptions of functional roles, regulatory interactions, and disease-causing variants. For oncology, in particular, genome analysis allowed deeper tumor characterization and identification of distinct molecular subtypes based on gene expression patterns. This genomic information is now a central component of pharmacogenomics.

All patients are the decisive beneficiaries of targeted therapies and pharmacogenomics research. In years past, particular cancer diagnoses were considered terminal, but because of improvements over the past 20 years in early detection and personalized treatments, some of these same malignancies are now treatable. In addition, the arsenal to fight cancer has grown beyond cytotoxics to include better-tolerated treatments with fewer severe side effects. Pharmacogenomics has helped define patient populations who are better suited to respond to a given therapy.

Learning Objectives:

• Understand the concept of pharmacogenomics;
• Describe the state of the art of the associated technologies; and
• Know current clinical applications on pharmacogenomics in oncology.

Fundamental 8B: Communicating Medical and Oncology Information to Health Care Professionals and Patients
14:30 – 15:30 (El Quixote)

Twitter and Virtual Journal Club: Stay Up to Date with Distance Learning
Felice Musicco, Istituti Fisioterapici Ospitalieri Regina Elena San Gallicano, Rome, Italy

Twitter is an online social networking service, accessible from any Internet-capable device. It is often used for integrating social networking with medical education and communications. It is also a very powerful tool that amplifies the content of scientific meetings to a wider audience, generating international engagement and global
In this lecture, we will discuss the mechanics of using Twitter, and we will discuss the suggestions and evidence for incorporating Twitter into many medical education contexts and symposia.

In this lecture, we will also discuss how the ISOPP Virtual Journal Club leverages internet technology. The journal club is intended to provide a way for oncology pharmacists to see articles published in Journal of Oncology Pharmacy Practice and to learn about developments in the field of oncology practice. Articles are posted monthly. To participate, read the article and then answer a series of online multiple choice questions about each article; after completing the questionnaire, participants will be emailed a personalized certificate. 23 issues of the ISOPP VJC have been published since 2012. We will discuss the way that VJC has been developed, how to participate and ideas to improve it through online discussions with Authors and Colleagues.

Learning Objectives:
- Discuss the use of Twitter for professional means
- Understand how to reply, favourite and or RT tweets;
- Understand the use of hashtags to engage in conversations;
- Discuss how to tweet through basic tweets, and tweets with photos and images; and
- Discuss the use of the ISOPP Virtual Journal Club.

**Social Media in Oncology, Risk and Benefit**
Gustavo Espinoza, Central de preparaciones oncológicas REDSANA, Santiago, Chile

Social media has had an impact in the treatment of cancer. The use of social media in medicine provides new opportunities for health care professionals and institutions to interact with patients and other professionals. Wide availability of public information on oncology motivates patients and families to become active seekers of medical information and participate in their care decisions. Social media platforms can be used for patient education, professional development, knowledge sharing, and for direct patient interaction. However, control of the information published, namely the credibility of the information available online, raises an ethical question, especially with regard to maintaining the trust and the bond between the health professional and the patient.

Learning Objectives:
- Understand how patients and health care professionals are utilizing social media in health-related information;
- Evaluate the use of new internet platforms in providing oncological information; and
- Recognize the advantages and disadvantages of using social media in oncology.

**Research 8C: Interacting with Professional Journals: Reviewing and Publishing**
14:30 – 15:30 (O’Higgins)
Alexandre Chan, National University of Singapore, Singapore
Barry Goldspiel, National Institutes of Health Clinical Center, Bethesda, MD, USA

Scholarly peer review is the process of subjecting an author’s scholarly work, research, or ideas to the scrutiny of others who are experts in the same field, before a piece of work is published in a journal. In this session, we will provide an overview on the purpose of peer review and publishing. We will discuss how to conduct a peer-review on a manuscript.

Learning Objectives:
- Understand the purpose of peer-review and publishing within the scientific process; and
- Discuss how to conduct a peer-review on a manuscript.
Refreshment Break
15:30 – 15:45  (Pedro de Valdivia C / El Quixote / O’Higgins)

Concurrent Sessions 9

Clinical 9A: Gastrointestinal Tumors Update
15:45 – 16:45  (Pedro de Valdivia C)
Jorge Gallardo, Clínica Alemana de Santiago, Instituto de Terapias Oncológicas Providencia, Santiago, Chile

Fundamental 9B: Dose Banding: Safety and Savings in One
15:45 – 16:45  (El Quixote)
Carole R. Chambers, Tom Baker Cancer Clinic Pharmacy, Calgary, AB, Canada
Johan Vandenbroucke, Ghent University Hospital, Ghent, Belgium
Dose banding is a concept that first emerged in oncology around 2001. This session will include learning objectives to understand the term ‘dose banding’ and discover different implementation ideas using dose banding. Audience participation will be encouraged so, those of you who have incorporated dose banding in your practice, please come prepared to share during this session. Although it may have initially started as a cost saving initiative the safety components will also be explored in this session.

Learning Objectives:
• Understand the term ‘dose banding’;
• Discover different implementation ideas using dose banding;
• Share with other ISOPP members your dose banding experience;
• Explore how dose banding can influence work flow; and
• Discuss opportunities for safety improvement with dose banding.

Fundamental 9C: Tools and Methods for Pharmaceutical Care Plans and Documentation
15:45 – 16:45  (O’Higgins)
Tools and Methods for Pharmaceutical Care Plans and Documentation
Klaus Meier, Heidekreis-Klinikum GmbH, Soltau, Germany
Together the community of hospital pharmacist in Estonia, the Chamber of Pharmacists Slovenia and the German Society for Oncology Pharmacy (DGOP) - under the auspices of the European Society of Oncological Pharmacy (ESOP) - has created a three-year EU project with the title: Empowering pharmacists to improve health care for oral chemotherapy patients: Establishment of a European best-practice model — EPIC.

The project aims to create an European best practice model for the development and implementation of supportive services for pharmacists in oral cancer therapy. Several tools are in use in order to support the sustainability of the program.

Learning Objectives:
• Identify the resistances that hinder the successful target for compliance;
• Learning what qualities pharmacists must have to advise patients sufficiently; and
• Develop patient to competent partners who can control their therapy confidently.

Development and Implementation: The Tools required by Clinical Pharmacists to Conduct Safe Chemotherapy Checks

Shinya Suzuki, National Cancer Center Hospital East, Kashiwa, Japan

Over the years, we have developed various tools for improving pharmacy services to ensure safe cancer chemotherapy. One of the important concepts in developing new clinical tools is to understand “what is a problem”, and what can be done to solve the problems. Recently, my colleagues at the pharmacy division of the National Cancer Center Hospital East and I developed a flowchart-type leaflet to manage patients’ adverse drug reactions due to chemotherapy, and chemotherapy regimen check sheets to manage safe cancer chemotherapy. (J Oncol Pharm Pract 2015, and Sage Open Med 2014) We not only developed the tools but we also implemented and validated the tools in order to document the data in daily practice. In this session, I would like to share details on what kinds of tools we have developed so far, and how we develop these new tools to ensure safe cancer chemotherapy.

Learning Objectives:
• Recognize and share useful tools for clinical pharmacy services;
• Understand how to develop and validate tools for clinical pharmacy services; and
• Share the experience and ideas we learned for ensuring safe cancer chemotherapy.

Closing Panel
Cultural Diversity and Awareness in Oncology
16:45 – 18:00 (Pedro de Valdivia AB)

Panellists: Sara Aguayo, Hospital Base San José Osorno, Osorno, Chile
Tiene Bauters, Ghent University Hospital, Ghent, Belgium
Harbans Dhillon, University Malaya Medical Centre, Kuala Lumpur, Malaysia
Peter Gilbar, Toowoomba Hospital, Toowoomba, Australia
Kellie Jones Weddle, Purdue University, Indianapolis, IN, USA
Shinya Suzuki, National Cancer Center Hospital East, Kashiwa, Japan
John Wiernikowski, McMaster Children’s Hospital, Hamilton, ON, Canada
Moderator: Rosalyn Sims, Children’s Hospital of Michigan, Troy, MI, USA

This will be a discussion to highlight some differences in customs and cultures that an oncology pharmacist may encounter in daily practice when working in a culturally and ethnically diverse community.

Learning Objectives:
• Discuss ways to relate to patients/family members or caregivers who may have different attitudes or customs in regards to interactions between genders;
• State different ways to overcome language barriers with patients and families;
• Describe some ways to overcome or work around treatment barriers when a patient or family may object to lifesaving therapies for cultural or religious reasons;
• Describe ways to explain to patients/families that homeopathic or alternative therapies may not be compatible with their treatment plan; and
• Identify some issues that could arise when treating patients from indigenous populations.
Awards and Closing Remarks
18:00 – 18:30  (Pedro de Valdivia AB)

Judith Smith, The University of Texas Health Science Center at Houston Medical School, Houston, TX, USA
Barry Goldspiel, National Institutes of Health Clinical Center, Bethesda, MD, USA
Alejandra Barahona, Hospital del Salvador, Santiago, Chile
Rowena Schwartz, ISOPP Past President, McKesson Specialty Health, The Woodlands, TX, USA
Harbans Dhillon, University Malaya Medical Centre, Kuala Lumpur, Malaysia

Capítulo de Químicos Farmacéuticos de Oncología Annual General Meeting
18:30 – 21:00  (Pedro de Valdivia C)

All Symposium participants are welcome to attend and CQFO members are encouraged to attend.
With over 75 years of experience in sterile manufacturing, and the widest range of solutions on the market, Grifols is the ideal partner to help make compounding safer.

Grifols’ sterile manufacturing expertise applied to the compounding pharmacy

Grifols

IV solutions that fit

Aesynt offers a full suite of IV robotic and workflow solutions designed to fit your goals and impact patient safety.

Learn more at aesynt.com/solutionsfit

Oncology

LaboratorioChile®
Calidad global para ti
Speaker Biographies

Sara Aguayo, Hospital Base San José Osorno, Osorno, Chile
Milan J. Anadkat, Washington University School of Medicine, St. Louis, MO, USA
Alain Astier, Henri Mondor University Hospitals, Paris, France
Tiene Bauters, Ghent University Hospital, Ghent, Belgium
Christian Caglevic, Fundación Arturo López Pérez, Santiago, Chile
Carole Chambers, Tom Baker Cancer Clinic Pharmacy, Calgary, AB, Canada
Alexandre Chan, National University of Singapore, Singapore
Mario Chiong Lay, University of Chile and Advanced Center for Chronic Diseases (ACCDIS), Santiago, Chile
Alejandro Corvalán, Pontificia Universidad Catolica de Chile, Santiago, Chile
Harbans Dhillon, University Malaya Medical Centre, Kuala Lumpur, Malaysia
Gustavo Espinoza, Central de preparaciones oncológicas REDSANA, Santiago, Chile
Martha Estacio, Instituto Nacional de Enfermedades Neoplasicas Eduardo Caceres Graziani, Lima, Peru
Ivonne Flores, Fundación Arturo López Pérez, Santiago, Chile
Jorge Gallardo, Clinica Alemana de Santiago, Instituto de Terapias Oncológicas Providencia, Santiago, Chile
Barry Goldspiel, National Institutes of Health Clinical Center, Bethesda, MD, USA
Claudio Gonzalez, Unidad Oncología, Hospital pediátrico Exequiel González Cortés, Santiago, Chile
Evelyn Handel, National Comprehensive Cancer Network, Ambler, PA, USA
R. Donald Harvey, Winship Cancer Institute of Emory University, Atlanta, GA, USA
Kellie Jones Weddle, Purdue University, Indianapolis, IN, USA
Tara Leslie, Tom Baker Cancer Centre and University of Alberta, AB, Canada
Annemeri Livinalli, Sociedade Brasileira de Farmacêuticos em Oncologia, São Paulo, Brazil
Klaus Meier, Heidekreis-Klinikum GmbH, Soltau, Germany
Jorge Morales Vallespin, Hospital Dr. Luis Calvo Mackenna, Santiago, Chile
Felice Musicco, Istituti Risioterapici Ospitalieri, Rome, Italy
Shaun O’Connor, Box Hill Hospital (Eastern Health), Box Hill, VIC, Australia
Pablo Ramirez, Catholic University, Santiago, Chile
Rowena Schwartz, McKesson Specialty Health, The Woodlands, TX, USA
Rosalyn Sims, Children’s Hospital of Michigan, Troy, MI, USA
Judith Smith, The University of Texas Health Science Center at Houston Medical School, Houston, TX, USA
Steve Stricker, Takeda Oncology, Florence, KY, USA
Shinya Suzuki, National Cancer Center Hospital East, Kashiwa, Japan
Julie Torode, Union for International Cancer Control (UICC), Geneva, Switzerland
Johan Vandenbroucke, Ghent University Hospital, Ghent, Belgium
John Wiernikowski, McMaster Children’s Hospital, Hamilton, ON, Canada
Sara Aguayo, Hospital Base San José Osorno, Osorno, Chile

Sara Aguayo is the Pharmacist in charge of the central admixture of oncological drugs of the Hospital base San José de Osorno. She graduated as a Pharmacist from the Universidad de Concepción in 2006. Since then she has been dedicated to oncology pharmacy. She has a Master's degree in Pharmaceutical Oncology by the Universidad de Valencia and other postgraduate degrees in palliative care and health administration. She is a member of the Chilean Chapter of Oncology Pharmacist since 2007 and an active member of the oncology committee of the hospital. Sara has gained practical experience in adult oncology patient.

Sara will be speaking in the following session:

• Closing Panel: Cultural Diversity and Awareness in Oncology

Milan J. Anadkat, Washington University School of Medicine, St. Louis, MO, USA

Dr. Milan Anadkat is an Associate Professor of Dermatology and Residency Program Director at Washington University School of Medicine. He graduated from the University of Akron and earned his medical degree at the Northeastern Ohio Universities College of Medicine. Dr. Anadkat performed his residency training at Washington University School of Medicine in St. Louis. He also completed a two-year clinical trials fellowship at Washington University School of Medicine.

In 2007, Dr. Anadkat joined the faculty of Washington University School of Medicine in St. Louis, MO. His clinical focus is in the area of complex medical dermatology, with a unique interest in oncodermatology. He is a national leader in the field of dermatologic therapeutics, graft-versus-host disease, and most notably, chemotherapy-induced adverse reactions. He has numerous publications and been invited to deliver many lectures on these topics.

Dr. Anadkat is a member of the American Academy of Dermatology, Medical Dermatology Society, American Professors of Dermatology, Society of Investigative Dermatology, and MASCC (Multinational Association of Supportive Care in Cancer). He has served on Work Groups and Task Forces for the American Academy of Dermatology, National Cancer Institute, MASCC, and NCCN. He is also on the Editorial Board for the Journal of Supportive Care in Cancer and Journal of the American Academy of Dermatology Case Reports.

Milan will be speaking in the following sessions:

• Plenary: Dermatologic Toxicities: The Superficial Side of Targeted Therapies
• Clinical 6A: Supportive Care Updates

Alain Astier, Henri Mondor University Hospitals, Paris, France

Professor Alain Astier carried out his pharmacy studies (Pharm D) in 1972 at the University of Paris V. He earned his PhD in organic and structural chemistry in 1976 at the Paris XI University. He graduated in cellular pharmacology and radiopharmacy. He has been Assistant Professor in pharmaceutical chemistry from 1977-1981, at Paris XI University. He was Professor of Clinical Pharmacy and Biotechnics (University of Lorraine) from 1997 to 2010 and he is Head of the department of Pharmacy, Henri Mondor University Hospital. He is member of the French Academy of Pharmacy and has been laureate of the prestigious Galien Prize for pharmaceutical research in 2001.

His current research interests include new formulations, analysis and stability of anticancer drugs, especially monoclonal antibodies. He has signed more than 220 research papers in peer-reviewed scientific journals and more than 300 communications in scientific congresses. He has been a member of numerous scientific committees and chairman of several international congresses.
Professor Astier is Vice-President of the ESOP and of the French Society of Oncology Pharmacy (SFPO). He is a member of the editorial board for several scientific journals. He is Editor-in-Chief of the Annales Pharmaceutiques Francaises, official journal of the French Academy of Pharmacy. He has been a member of the Board of Director of ECCO in 2012-2014.

Alain will be speaking in the following session:

- Fundamental 2B: Pharmacovigilance Plan for Biologics and Biosimilar Antibodies: Is it Really Useful?

Tiene Bauters, Ghent University Hospital, Ghent, Belgium

Tiene Bauters has been a clinical pharmacist at Ghent University Hospital (Belgium) since 2003. She earned her Doctor of Pharmacy degree from Ghent University. For almost 10 years, she has been involved in Pediatric Hematology, Oncology and Stem Cell Transplantation. In this role, she provides clinical pharmacy services with a focus on supportive care. She has authored numerous peer-reviewed publications on topics related to pediatric oncology and presented at many international conferences. She has been an ISOPP member since 2008 and served as general secretary member since 2014. Tiene Bauters is currently a member of ISOPP, SIOP and ASBMT. She is the European pharmacist’s representative for FACT-JACIE standards.

Tiene will be speaking in the following sessions:

- Clinical 6B: Bone Marrow Transplant Update
- Research 7B: How Pharmacists Can Integrate Research into Daily Oncology Practice
- Closing Panel: Cultural Diversity and Awareness in Oncology

Christian Caglevic, Fundación Arturo López Pérez, Santiago, Chile

Christian Caglevic is a Medical Oncologist who graduated from the Universidad de Chile with a Postgraduate in Molecular Oncology and Targeted Therapies at the Universidad del Salvador, Buenos Aires, Argentina. Currently, he is a Medical Oncologist at Fundación Arturo López Pérez of Santiago, Chile and Head of the Early Development of Drugs Unit at the same institution. Dr. Caglevic has been principal investigator and sub investigator of several clinical trials on solid tumors. He has several publications on solid tumors treatment and also in basic sciences. He participates in ASCO as a collaborative member and is also a member of ESMO, ILOGI, Sociedad Médica de Chile, IASLC, SIOG, Sociedad Chilena de Oncología Médica, Grupo Latinoamericano de Tumores Gastrointestinales. Dr Caglevic is a Board Member of Ecancer Medical Science and recent reviewer of several journals, such as Oncotarget and Revista Médica de Chile. He was the past Director of the Latin American Symposium of Gastroenterological Cancer (SLAGO), and current leader of the Latin American Consensus in Pancreatic Cancer.

Christian will be speaking in the following session:

- Plenary: Clinical Impact and Recent Outcomes of Immunotherapy in Solid Tumours: Is it the Pathway for Cancer Cure?

Carole R. Chambers, Tom Baker Cancer Clinic Pharmacy, Calgary, AB, Canada

Carole Chambers is the Pharmacy Director of Cancer Services with Alberta Health Services, with over 50 peer reviewed publications. She currently serves on the provincial advisory group for pCODR and the panCanadian pricing negotiating teams dealing with access issues to new oncology agents. She also joined the Board of the Institute of Safe Medication Practice (ISMP-Canada). Carole has remained active in ISOPP since completing
her term as ISOPP President in 2010 as she sits on the JOPP Editorial Board. She served on the Scientific Committee for ISOPP in Montreal 2014, and is a member of the team generating the ISOPP virtual journal club. She holds an ISOPP Fellowship as well as the Helen McKinnon award recognizing her significant contribution to ISOPP and oncology pharmacy practice.

Carole will be speaking in the following session:

- **Fundamental 9B: Dose Banding: Safety and Savings in One**

**Alexandre Chan, National University of Singapore, Singapore**

Alexandre Chan, Pharm.D., MPH, FCCP, BCPS, BCOP is a Deputy Head and a tenured Associate Professor of the Department of Pharmacy, Faculty of Science at the National University of Singapore (NUS) and Duke-NUS Medical School. He is also appointed as an adjunct faculty at University of California, San Francisco School of Pharmacy and University of the Pacific Thomas J. Long School of Pharmacy and Health Sciences. He is also a program director for the National Oncology Pharmacy Residency Program in Singapore. Currently, he is dually board certified in Pharmacotherapy and Oncology Pharmacy.

Dr. Chan has published over 120 full-length peer-reviewed manuscripts in a wide array of cancer supportive care topics, including chemotherapy-induced nausea and vomiting, myelosuppression, cognitive impairment, dermatological toxicities and cancer-related fatigue. He was the recipient of the Young Scientist Award from National University of Singapore in 2013, and he was elected as an American College of Clinical Pharmacy (ACCP) Fellow in 2014. He was also the recipient of the Steven M. Grunberg Memorial Award from Multinational Association of Supportive Care in Cancer in 2015.

Alexandre will be speaking in the following sessions:

- **Clinical 2A: Antiemetic Updates**
- **Clinical 5A: Hematological Cancer Updates**
- **Fundamental 8C: Interacting with Professional Journals: Reviewing and Publishing**

**Mario Chiong Lay, University of Chile, Santiago, Chile**

Dr. Mario Chiong is Associate Professor at the Department of Biochemistry and Molecular Biology at the Faculty of Chemical and Pharmaceutical Sciences, University of Chile. Beside its academic activities Dr. Chiong is also an Associate Investigator in the Advanced Center for Chronic Diseases (ACCDIS). This Center is a multidisciplinary research initiative that study the natural history of cardiovascular diseases and cancer in the Chilean population. He directs a laboratory of six graduate students/postdoctoral fellows and one technician. He began to work in pharmacogenomics more than a decade ago studying drug efficacy and adverse effects in patients with heart failure. Actually Dr. Chiong has more than 100 papers published in ISI-ranked journals and 6 patents.

Dr Chiong is a Biochemist (University of Chile) and received a PhD in Pharmacology (University of Chile). In the area of Pharmacology, he has performed Research Training in the National Institute of Biological Standards and Control (UK) and in the Food and Drug Administration (USA). He is professor in the careers of Pharmaceutical Chemist, Biochemistry and Medicine and in the MSc and PhD programs of Biochemistry, Pharmacology, Pharmaceutical Science, and Biomedical Science, at University of Chile.

Mario will be speaking in the following session:

- **Clinical 8A: Application of Pharmacogenomics in Daily Clinical Practice**
Alejandro Corvalán, Pontificia Universidad Catolica de Chile, Santiago, Chile

Alejandro Corvalán is a full-time medical researcher at Pontificia Universidad Catolica de Chile, involved in translational cancer research at basic, clinical and population levels. His research is primarily focused on cancer epigenetics with an emphasis on the discovery and validation of tumor suppressor genes inactivated by DNA methylation. These discoveries act as potential biomarkers for the early diagnosis of cancer, monitoring treatment response and developing new treatments. Through this research, he is developing a novel screening and triage test for the early detection of gastric cancer based on cell free DNA in plasma. He is also investigating the role of two p53-dependant tumor suppressor genes, Reprimo and p73, in the pathogenesis of gastric cancer. In addition to this he has a strong interest in genomics, specifically exploring cancer heterogeneity through a data-mining approach by using existing databases and open-source / in-house bioinformatic softwares.

Alejandro will be speaking in the following session:

- Research 2C: Epigenetic Bases of Gastric Cancer: From Pathogenesis to the Potential Identification of New Targets for Prevention and Treatment

Harbans Dhillon, University Malaya Medical Centre, Kuala Lumpur, Malaysia

Harbans Dhillon started working as a manufacturing pharmacist at the University Malaya Medical Centre in 1978. She was appointed as Chief Pharmacist in April 2015 and then promoted to Deputy Director (Professional) in September 2015. She was the President of PENSMA (Parenteral and Enteral Nutrition Society of Malaysia) from 1998-2010 and president of PENSA (Parenteral and Enteral Nutrition Society of Asia) from 2007-2009. Currently she is an advisor to both societies.

Harbans is the president-elect of ISOPP and was on the secretariat 2007-2009. She was also the President of Asia4safehandling Organisation which promotes safe handling of cytotoxic drugs in Asia 2009-2010 and is still a board member.

Harbans will be speaking in the following sessions:

- Fundamental 4A: Oral Medication Adherence and Management in Oncology
- Panel: Developing to Established….How to Define Oncology Pharmacy as a Specialty
- Closing Panel: Cultural Diversity and Awareness in Oncology

Gustavo Espinoza, Central de preparaciones oncológicas REDSANA, Santiago, Chile

Since 2009, Gustavo Espinoza has been the pharmacist in charge of the manufacturing process supervision inside the central of oncological admixture, belonging to the highly specialized pharmacy RedSana S.A. He earned his pharmacist degree from the Universidad de Chile and for more than 8 years he has been developing his career in several aspects of the oncology specialty.

Nowadays, his main role is to guarantee the quality of the oncological admixtures that are distributed through different medical centers across the country. He has participated as a speaker in different symposiums and congresses such as SLAURO, SLAGO, Chilean Congress of Cancerology and the Chilean Congress of Mastology, spreading scientific information concerning oncology pharmacy practice. He is currently a member of the Chapter of Chilean Oncology Pharmacists and he is responsible for the communications and social medias departments of the society, promoting and collaborating the organization, and its workshops and conferences in oncology pharmacy throughout Chile.

Gustavo will be speaking in the following session:

- Fundamental 8B: Communicating Medical and Oncology Information to Health Care Professionals and Patients
Martha Estacio, Instituto Nacional de Enfermedades Neoplasicas Eduardo Caceres Graziani, Lima, Peru

Martha Estacio is a clinical pharmacist at the Instituto Nacional de Enfermedades Neoplasicas Eduardo Caceres Graziani. She graduated from the Universidad Nacional Mayor de San Marcos and has also obtained postgraduate studies in clinical pharmacy. For six years she was dedicated to the preparation of Parenteral Nutrition, then was pharmacist in charge of the manufacturing process and superviser inside the central of oncological admixture and nowadays responsible for the development of Pharmacovigilance and Clinical Pharmacy unit at the Instituto Nacional de Enfermedades Neoplasicas Eduardo Caceres Graziani. Also, she is an associate professor of the Universidad Particular Norbert Wiener, teaching classes of pharmacotherapy. She is a member of scientific societies including the Asociacion Peruana de Terapia Nutricional, participating as a speaker in the areas of oncology and parenteral nutrition.

Martha will be speaking in the following session:
- **Clinical 4C: Oncology Patients and Special Circumstances**

Ivonne Flores, Fundación Arturo López Pérez, Santiago, Chile

Ivonne Flores is a clinical pharmacist at the Instituto Oncológico Fundación Arturo López Pérez. She graduated from the Universidad de Chile and she has obtained postgraduate studies in hospital and clinical pharmacy. Since then she has dedicated herself professionally to oncology pharmacy, initially in the preparation of cytotoxic drugs and later responsible for the development of Pharmacovigilance and Clinical Pharmacy Program at the Fundación Arturo López Pérez, developing her work in the clinical services Ambulatory Chemotherapy, Medicine, Surgery and Intensive Care Unit. Also, she is an associate professor of the Universidad San Sebastian, teaching classes of oncology clinical pharmacy and is a professor and guide of internship pharmacy students. As well, she is a member of scientific societies such as the Society of Hospital Pharmacy and the Chilean Society of Intensive Medicine, participating as a speaker and in the organization of congresses, in the areas of oncology and critical medicine.

Ivonne will be speaking in the following session:
- **Clinical 2A: Antiemetic Updates**

Jorge Gallardo, Clínica Alemana de Santiago, Instituto de Terapias Oncológicas Providencia, Santiago, Chile

Jorge Gallardo E. was born in the city of Coquimbo, Chile, and studied medicine at the University of Concepcion. He studied Internal Medicine and did his specialization in Medical Oncology, Faculty of Medicine, Clinical Hospital of the University of Chile. Jorge studied improvement, specialization in oncology, hematology and bone marrow transplantation in Germany. He also was awarded with a scholarship for a course of “Improvement in oncology clinic”, in the United States. Jorge is a medical oncologist and his clinical work is done in a private health institution on patients with solid tumors, especially tumors GI. He is also President of Chile Cancer Foundation which is the organized of the Symposium Latinoamericano de Gastroenterologia Oncologica (SLAGO).

Jorge will be speaking in the following session:
- **Clinical 9A: Gastrointestinal Tumors Update**
Peter Gilbar, Toowoomba Hospital, Toowoomba, Australia

Peter Gilbar is a Pharmacist Consultant – Cancer and Palliative Care Services and Senior Lecturer – School of Medicine, University of Queensland at Toowoomba Hospital, Australia. He holds a Bachelor of Pharmacy from the University of Queensland, a Masters in Palliative Care from Flinders University, and Fellowships from the Society of Hospital Pharmacists of Australia (SHPA) and International Society of Oncology Pharmacy Practitioners (ISOPP). He serves on the Editorial Board of the Journal of Oncology Pharmacy Practice and Journal of Pediatric Oncology, and is a member of the ISOPP Education and Membership Committees. Santiago is the 12th ISOPP Symposia he has attended. Peter is a regular contributor to peer reviewed journals (over 60 publications) and presenter at oncology conferences. His particular areas of interest and research include medication safety, symptom management and rural oncology practice.

Peter will be speaking in the following sessions:
- Clinical 4C: Oncology Patients and Special Circumstances
- Clinical 5C: End of Life Care Discussion Session
- Closing Panel: Cultural Diversity and Awareness in Oncology

Barry Goldspiel, National Institutes of Health Clinical Center, Bethesda, MD, USA

Dr. Barry Goldspiel is Acting Chief of the National Institutes of Health Clinical Center Pharmacy Department in Bethesda, Maryland. He received his B.S. in Pharmacy from the Arnold and Marie Schwartz College of Pharmacy in Brooklyn, New York and a Doctor of Pharmacy degree from the University of Texas Health Science Center in San Antonio. He completed a Specialized Residency in Oncology Pharmacy Practice at the Audie L. Murphy Veterans Hospital in San Antonio.

Dr. Goldspiel is an active member of several pharmacy societies, including the American Society of Health-System Pharmacists (ASHP), American College of Clinical Pharmacy (ACCP), the International Society of Oncology Pharmacy Practitioners (ISOPP), and the Hematology/Oncology Pharmacy Association (HOPA). He is a fellow of ASHP, ACCP, HOPA, and ISOPP and an honorary member and past-president of ISOPP and HOPA. Dr. Goldspiel is the founding Editor of the Journal of Oncology Pharmacy Practice, the official publication of ISOPP.

Barry will be speaking in the following sessions:
- Fundamental 3C: Education, Competency and Mentorship
- Research 8C: Interacting with Professional Journals: Reviewing and Publishing

Claudio Gonzalez, Unidad Oncología, Hospital Pediátrico Exequiel González Cortés, Santiago, Chile

Claudio González Muñoz is a Clinical Pharmacist at the Exequiel González Cortes Hospital (EGCH). EGCH is an important Pediatric Hospital located in Santiago, Chile. Claudio graduated from The Pontifical Catholic University of Chile (PUC) and has a diploma in Clinical investigation and a diploma in Clinical Studies from University of Chile. Claudio is responsible for the Clinical Pharmacy Unit, specifically in the oncology and intensive care units. He takes part in the daily clinical visits with oncology, Infectious Disease, intensive care and pediatric specialists to reach the rational use of medicines. His main lines of scientific research are antimicrobial pharmacokinetic and pharmacovigilance. Currently he is member of the American College of Clinical Pharmacy (ACCP), Clinical Pharmacist Division of Chilean Intensive Medicine Society (SOCHIMI) and the Sociedad Chilena de Farmacia Asistencial (SCHFA).

Claudio will be speaking in the following session:
- Clinical 6A: Supportive Care Updates
Evelyn Handel, National Comprehensive Cancer Network (NCCN), Ambler, PA, USA

Evelyn Handel, PharmD, BCPS, BCOP is currently an Oncology Scientist at the National Comprehensive Cancer Network® (NCCN®) where she helps develop and maintain the NCCN Drugs & Biologics Compendium® and NCCN Chemotherapy Order Templates®, among other projects. Prior to joining NCCN, Dr. Handel was an Oncology Clinical Pharmacist Specialist at Roswell Park Cancer Institute working with the inpatient and outpatient solid tumor services. In this role, she provided chemotherapy-related patient counseling as well as side effect management through a collaborative drug therapy management (CDTM) program, helped create a pharmacist-led oral chemotherapy monitoring program, and precepted pharmacy students and residents. She also served as adjunct clinical faculty for both D'Youville College of Pharmacy and the University at Buffalo School of Pharmacy. She earned her Doctor of Pharmacy from Ohio Northern University and completed a PGY1 Pharmacy Practice Residency at Oregon Health & Science University Hospital followed by a PGY2 Oncology Pharmacy Residency at the H. Lee Moffitt Cancer Center.

Evelyn will be speaking in the following session:

• Clinical 1A: Solid Tumor Updates

R. Donald Harvey, Winship Cancer Institute of Emory University, Atlanta, GA, USA

R. Donald Harvey, PharmD, FCCP, BCOP is Associate Professor of Hematology and Medical Oncology at the Winship Cancer Institute of Emory University, and serves as director of the Winship Cancer Institute’s Phase I Clinical Trials Unit and Section. He has established an active clinical pharmacology research program in cancer at Emory with the goal of using pharmacokinetic, pharmacodynamic, and other tools to improve individualization of therapy and clinical outcomes.

Donald will be speaking in the following sessions:

• Plenary: Novel Immunotherapy for Melanoma: Mechanisms, Outcomes, and Future Strategies
• Research 4B: Investigational Agents Update
• Research 6C: How to Write your First Grant

Kellie Jones Weddle, Purdue University, Indianapolis, IN, USA

Kellie Jones Weddle, BCOP, FCCP is Clinical Professor of Pharmacy Practice, College of Pharmacy, Purdue University and Adjunct Assistant Professor of Medicine, Department of Medicine, Indiana University School of Medicine. She received her B.S. (Pharmacy) and PharmD from the University of Kentucky. Dr. Weddle also completed Pharmacy Practice and Oncology Specialty residencies at the University of Kentucky. She is a board certified oncology pharmacist. She has worked as an Oncology Clinical Specialist at The University of Texas M. D. Anderson Cancer Center in Houston, Texas. During her seven years there, her primary focus was in breast and gynecologic malignancies. In September 2007, Dr. Weddle joined the faculty at Purdue University. Her clinical practice site is at Indiana University Simon Cancer Center working with the medical and gynecologic oncology services.

Kelly will be speaking in the following sessions:

• Clinical 1A: Solid Tumor Updates
• Closing Panel: Cultural Diversity and Awareness in Oncology
Tara Leslie, Tom Baker Cancer Centre and University of Alberta, Calgary, AB, Canada

Tara Leslie attained her Bachelor of Science in Pharmacy (BSP) degree from the University of Saskatchewan in 1997, obtained her Board Certification in Oncology Pharmacy (BCOP) in 2010, and acquired her Additional Prescribing Authority in 2013. She is a Clinical Pharmacist at the Tom Baker Cancer Centre in Calgary, Canada and a Clinical Assistant Professor with Experiential Education at the Faculty of Pharmacy, University of Alberta. For several years, Tara’s primary area of clinical practice has been with hematologic malignancy and bone marrow transplant patients. Tara is very involved with oncology education of pharmacy students as a preceptor and as an educator on topics such as hematologic malignancy, chemotherapy safety and oncology related symptom management. Tara is an active member of ISOPP and the Canadian Association of Pharmacy in Oncology, also known as CPhO. She serves as Chair for the CPhO Pharmacist Education Committee and is Co-Chair of the CPhO 2020 Task Force.

Tara will be speaking in the following sessions:
- Clinical 5A: Hematological Cancer Updates
- Panel: Developing to Established….How to Define Oncology Pharmacy as a Specialty

Annemeri Livinalli, Sociedade Brasileira de Farmacêuticos em Oncologia, São Paulo, Brazil

Annemeri Livinalli graduated as a pharmacist with a Masters degree in pharmaceutical sciences and a postgraduate degree in health administration and clinical pharmacology. Annemeri has gained practical experience in Pediatric Oncology and theoretical knowledge in different areas, including Geriatric Oncology. She has been a member of the Sobrafo board (Brazilian Society of Oncology Pharmacist) since 2007, currently as director of communication. Annemeri has also been an Ad-Hoc reviewer of Journal of Oncology Pharmacy Practice since 2008.

Annemeri will be speaking in the following sessions:
- Panel: Developing to Established….How to Define Oncology Pharmacy as a Specialty
- Clinical 7A: Optimizing Care in the Older Adult with Cancer

Klaus Meier, Heidekreis-Klinikum GmbH, Soltau, Germany

Klaus Meier is CEO of the Department for Clinical and Hospital Pharmacy, HKK trust Soltau, Lower Saxony, Germany. He received a master of theology and paedagogics in 1975. He has been a pharmacist since 1981, and received his Clinical certification in 1989 Oncology certification in 1995. Klaus Meier developed the QuapoS (Quality standard for Oncology Pharmacy Service). Five editions have been published since 1996 in 27 languages. In 2009 he became fellow of the EACS (European Academy for Cancer Sciences) and is acting as Vice Director at IFACHS (Institute for applied healthcare sciences).

From 1998 to 2000 Klaus was President of ISOPP. For four years he was a member of the board of directors of the European CanCer Organisation (ECCO), and is President of the German Society for Oncology Pharmacy (DGOP) as well for the European Society for Oncology Pharmacy (ESOP), which is accredited at EMA as HCPS (Health Care Professional Society).

Klaus Meier has been the editor-in-chief of the EJOP (European Journal of Oncology Pharmacy) since 2007.

Klaus will be speaking in the following sessions:
- Panel: Developing to Established….How to Define Oncology Pharmacy as a Specialty
- Fundamental 9C: Tools and Methods for Pharmaceutical Care Plans and Documentation
Jorge Morales Vallespín, Hospital Dr. Luis Calvo Mackenna, Santiago, Chile

Jorge Morales Vallespín is a Clinical Pharmacist graduate from Catholic University of Chile (PUC) with training in Clinical Pharmacology and Pharmacokinetics. He has a Master of Health Administration PUC and has worked at Luis Calvo Mackenna Hospital (HLCM) since 2005. He has been responsible for the development and implementation of the Clinical Pharmacology Program at the Oncology and Bone Marrow Transplant Units since 2006. Stay Pharmaceutical Pharmacy Service Clinic, St. Jude Children's Research Hospital, Memphis, USA, 2007 and 2009: “Applications of Clinical Pharmacy and Clinical Pharmacokinetics in Pediatric Oncology”. He served as head of the unit from that date until 2015. Actually, head of hospital pharmacy at HLCM, Performance in teaching, research and training in conjunction with the Oncology Program and Bone Marrow Transplant HLCM-International Outreach St Jude Hospital. He is a reviewer for Chilean and foreign scientific journals, scientific articles and participates in research associated with pharmacogenomic pharmacokinetics of neutropenic patients and pediatric ALL patients.

Jorge will be speaking in the following session:

- Clinical 3A: Pediatrics/Adolescents/Young Adults Update

Felice Musicco, Istituti Fisioterapici Ospitalieri Regina Elena San Gallicano, Rome, Italy

Felice Musicco is the Pharmacy Director of the External Hospital Pharmacy with the Istituti Fisioterapici Ospitalieri (IFO) in Rome. IFO is a public research oncological and dermatological hospital. He is also responsible for hospital pharmacovigilance services. Prior to joining IFO, Felice was a Military Pharmacist at “Celiò” Military Hospital in Rome and at the Military Hospital in Chieti.

Since 2007, Felice has been Chair of the ISOPP Publications Committee. He is a member of the team generating the ISOPP Virtual Journal Club. He was the first administrator of the ISOPP facebook page and promoter of twitter use at ISOPP symposia. Santiago is the 5th ISOPP Symposium he will have attended.

Felice served as Chief of the website editorial board of the Italian Society of Hospital Pharmacists. His particular areas of interest and research include medication safety, reporting drug adverse events in both clinical and experimental setting. Other areas of interest are information technology applied to pharmaceutical care (relational databases, mobile technology, web editing, social media and Internet).

Felice will be speaking in the following session:

- Fundamental 8B: Communicating Medical and Oncology Information to Health Care Professionals and Patients

Shaun O’Connor, Box Hill Hospital (Eastern Health), Box Hill, VIC, Australia

Shaun O’Connor is the Senior Oncology pharmacist at Eastern Health in Melbourne, Australia. He has served on the ISOPP Secretariat as a general member for the past 3 years, and was a leader on the ISOPP website redesign task force. He was on the Organising Committee for the ISOPP International Symposium in 2012 as well as the ISOPP Regional Symposia in 2011, 2013 and 2015, which were all held in Melbourne. He has professional interests in malignant haematology and workflow redesign, and social interests in Aikido and tennis.

Shaun will be speaking in the following sessions:

- Fundamental 5B: Lean Thinking with the Toyota Production System
- Panel: Developing to Established….How to Define Oncology Pharmacy as a Specialty
Pablo Ramirez, Catholic University, Santiago, Chile

Pablo Ramirez, MD, completed a Hematology Oncology Fellowship at Catholic University in Santiago in 2004 followed by a Malignant Hematology Fellowship at Washington University in St Louis in 2009 and an Advanced Training Program in Hematopoietic Cell Transplantation at the University of Minnesota in Minneapolis in 2010. Currently he is an Assistant Professor at the Hematology Oncology Department at Catholic University. He has published articles in Blood, BBMT, BMT and RBHH among others. He is a member of ASH, ASBMT, SOCHIHEM and Sociedad Chilena de Trasplante. He participates as a member of EUNACOM and the Comisión Nacional de Acreditación.

Pablo will be speaking in the following session:

- Clinical 6B: Bone Marrow Transplant Update

Rowena Schwartz, McKesson Specialty Health, The Woodlands, TX, USA

Rowena N. Schwartz is Vice President of Clinical Content and Pharmacy Operations at McKesson Specialty Health. She received a Bachelor of Science at the College of Pharmacy, University of Illinois and Doctor of Pharmacy at the University of Texas. She completed a fellowship in Oncology Drug Development at the University of Texas. Dr. Schwartz has spent much of her Oncology Pharmacy career in clinical practice at the University of Pittsburgh / University of Pittsburgh Cancer Institute. She was Director of Oncology Pharmacy Services at the Johns Hopkins Hospital and maintained an active clinical practice at the Sidney Kimmel Cancer Center. She has taught at Pharmacy Schools at the University of Pittsburgh, Duquesne University, University of Maryland, Charleston College of Pharmacy, University of Houston and Misr International University in Cairo, Egypt.

Rowena is a member of the American Society of Health System Pharmacist, Hematology and Oncology Pharmacy Association, Oncology Nursing Society, and the International Society of Oncology Pharmacy Practice.

Rowena will be speaking in the following sessions:

- Fundamental 3B: USP 800 Implementation and Practical Considerations
- Research 4B: Investigational Agents Update
- Panel: Developing to Established….How to Define Oncology Pharmacy as a Specialty
- Clinical 7A: Optimizing Care in the Older Adult with Cancer

Rosalyn Sims, Children’s Hospital of Michigan, Troy, MI, USA

Rosalyn Sims has been a Clinical Pharmacy Specialist in Hematology/Oncology at Children’s Hospital of Michigan for 18 years. She is a graduate of Emory University, with a bachelor’s degree in chemistry, and she received her PharmD from Mercer University College of Pharmacy both in Atlanta, Georgia.

She has published several articles in scientific journals on topics which include rasburicase, recombinant factor VIIa, triple antifungal therapy, and carboplatin desensitization. Her most recent publication is the results of a study about differences in vincristine metabolism in pediatric leukemia patients of different racial groups.

Rosalyn has been an ISOPP member since 1998. She has been an active member of the Membership and Finance committee and has served as the committee chair. She is also a former General Secretariat member. Rosalyn is dedicated to the field of Oncology Pharmacy, especially for pediatric patients.

Rosalyn will be speaking in the following session:

- Research 7B: How Pharmacists Can Integrate Research into Daily Oncology Practice
Judith Smith, The University of Texas Health Science Center at Houston Medical School, Houston, TX, USA

Dr. Judith A. Smith is a Director of the Women's Health Integrative Medicine (WHIM) Research Program and an Associate Professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at The University of Texas Health Science Center at Houston Medical School. She also has faculty appointments at the University of Houston, College of Pharmacy and the UT Graduate School of Biomedical Sciences. Dr. Smith received a Bachelor of Science in Pharmacy and her Doctor of Pharmacy degree from Union University Albany College of Pharmacy. She completed her residency in Pharmacy Practice and Oncology Pharmacy Practice at the National Institutes of Health followed by a fellowship in Clinical Pharmacology at UTMDACC. Upon completion of her fellowship, she joined the Faculty at UT MD Anderson. She has been Board Certified in Oncology Pharmacy and Certified Professional in Healthcare Quality.

Her research focus is directed at understanding drug disposition in patients in relationship to efficacy and toxicity with an emphasis on the integration of herbal & nutritional supplements with traditional Western Medications for treatment of cancer, cancer prevention, menopausal systems, and obesity. We conduct various drug development studies with intent to go from bench to bedside and back. The mission of the Women's Health Integrative Medicine Research Program is to advance the progress of the safe and effective use of nutritional and herbal supplements with pharmacologic modalities as it relates to women's health and cancer through innovative thinking, systematic methodology and collaborative interactions throughout the UTHouston System and global research community. Current ongoing studies are discussed on our program website: https://go.uth.edu/WHIMResearchProgram.

Judith will be speaking in the following sessions:

- Research 1B: Research with Complementary Alternative Medications in Oncology
- Fundamental 3C: Education, Competency and Mentorship
- Research 6C: How to Write your First Grant
- Research 7B: How Pharmacists Can Integrate Research into Daily Oncology Practice

Steve Stricker, Takeda Oncology, Florence, KY, USA

Dr. Steve Stricker currently serves as an Associate Director of US Medical Affairs Oncology for Takeda Oncology. After finishing his doctor of pharmacy degree at the University of Missouri in Kansas City, he completed his PGY-1 pharmacy residency at the University of North Carolina and a PGY-2 hematology/oncology pharmacy residency at Emory Healthcare in Atlanta, Georgia.

Dr. Stricker has held numerous leadership and advisory positions within the International Society of Oncology Pharmacy Practitioners (ISOPP), Hematology/Oncology Pharmacy Association (HOPA), American Society of Blood and Marrow Transplantation (ASBMT), and other professional pharmacy organizations. He has been an invited speaker, lecturer, and visiting faculty member for conferences, workshops and schools of pharmacy throughout North America, Europe, Asia and Australia.

Additionally, Dr. Stricker has authored more than 50 published manuscripts, invited editorials and textbook chapters and has been the recipient of several clinical practice and teaching awards including the 2013 HOPA New Practitioner Award.

Steve will be speaking in the following session:

- Fundamental 4A: Oral Medication Adherence and Management in Oncology
Shinya Suzuki, National Cancer Center Hospital East, Japanese Society of Pharmaceutical Oncology, Kashiwa, Japan

Shinya Suzuki is a clinical pharmacist at the National Cancer Hospital East (NCCHE) in Japan. After he finished residency, he received his board certification in Oncology Pharmacy from the Japanese Society Hospital Pharmacist and Japanese Society of Pharmaceutical Health Care and Sciences. Shinya is a delegate of the Japanese Society of Pharmaceutical Oncology (JASPO), which has over 2,000 members and accredits Oncology Pharmacy certification, and is a member of the Clinical Research committee. He is also a member of ISOPP, HOPA, and a delegate of ESOP. He is a faculty member of the EXCEMED Preceptorship course in head and neck cancer.

Shinya will be speaking in the following sessions:

• Fundamental 3B: USP 800 Implementation and Practical Considerations
• Fundamental 9C: Tools and Methods for Pharmaceutical Care Plans and Documentation
• Closing Panel: Cultural Diversity and Awareness in Oncology

Julie Torode, Union for International Cancer Control (UICC), Geneva, Switzerland

Based in Geneva, Julie Torode is Deputy CEO, Advocacy and Networks Director of the Union for International Cancer Control (UICC). In addition to managing some of the UICC flagship publications such as the TNM classification series and the International Journal of Cancer, Dr Torode has also been involved in the UICC World Cancer Day campaigns which focused on improving prevention awareness and national population-based cancer registries, the development of paediatric oncology projects in low- and middle-income countries, and cervical cancer prevention and control programmes. More recently Julie has led UICC’s advocacy activities, with a particular focus on the follow up to the 2011 UN High-level Meeting on Non-communicable Diseases (NCDs).

Julie will be speaking in the following session:

• Opening Plenary: Access to Cancer Medicines: Global Disparities Deserve Global Attention

Johan Vandenbroucke, Ghent University Hospital, Ghent, Belgium

Johan Vandenbroucke graduated as a pharmacist in 1979 from Ghent University, completing his Pharm D as a hospital pharmacist in 1981. Since then he has worked in the Ghent University Hospital and became Senior Pharmacist for the Production Department in 2001.

Johan joined ISOPP in 1998 and has participated in every meeting since then (except the Washington congress) both as delegate and as speaker. He took the position as co-chair of the standards committee and became a Secretariat member, President Elect, President (2010-2012) and is the current Treasurer on the board of ISOPP.

Johan will be speaking in the following session:

• Fundamental 9B: Dose Banding: Safety and Savings in One
John Wiernikowski, McMaster Children's Hospital, Hamilton, ON, Canada

John Wiernikowski obtained his pharmacy degree from the University of Toronto (1985) and PharmD from the State University of New York at Buffalo (1987). He started working with the Paediatric Haematology/Oncology service at McMaster University in 1987 where his research interests are supportive care related; focusing primarily on evidenced based management of febrile neutropenia and musculoskeletal morbidity of cancer treatment in children. He also has a keen interest in international health, particularly in developing countries. In 1995 he was a Fellow of the International Union against Cancer (UICC) and traveled to South America as part of a health care team examining health care resources for children with cancer. As part of that initiative John has established numerous links with pharmacists in developing countries and has an ongoing interest in establishing educational and training programs for pharmacists in these parts of the world.

John is a full member of the Children's Oncology Group (COG) and is actively involved in research endeavours of this group, particularly with Neuroblastoma. John has been involved with the Pediatric Oncology Group of Ontario since 1987 and was awarded the POGO Companion Award in 2005. John has also been a member of the Canadian Association of Pharmacy in Oncology since its inception, and served as Treasurer from 2004-2007. John has been a member of ISOPP since the ISOPP Symposium in Toronto; and is a long standing member of both the Research and Education committees. John served on the ISOPP Secretariat as a general member from 2006-2008, and as President Elect 2010-2012 and ISOPP President from 2012-14. John currently serves as the ISOPP Secretary. For his ongoing contributions to ISOPP, John was named a Fellow of the Society in 2008.

John will be speaking in the following sessions:

- Clinical 3A: Pediatrics/Adolescents/Young Adults Update
- Closing Panel: Cultural Diversity and Awareness in Oncology
Fresenius Kabi — caring for life

- with an innovative product portfolio
- with total cancer care concepts
- with outstanding services
- through a trusting partnership

www.fresenius-kabi.com